Johnson & Johnson (JNJ) KPIs and segments
Close on Nov 18, 2026Market cap $656.47BP/E 41.4Yield 1.88%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Johnson & Johnson · năm tài chính kết thúc 52/53-week fiscal year ending on the Sunday nearest December 31 (FY2025 ended December 28, 2025; Q3 2026 ended September 27, 2026)
Nhìn nhanh KPI của Johnson & Johnson: 51 chỉ số vận hành, trong đó có Consolidated sales to customers, Innovative Medicine Segment Total và Neuroscience Therapeutic Area Total, lấy từ 139 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Innovative Medicine($M)2 | 16,757 | 16,384 | 15,426 | 15,763 | 15,563 | 15,202 | 13,873 | 14,332 | 14,580 | 14,490 | 13,562 | 13,722 | |
U.S.($M) | 10,447 | 9,979 | 8,871 | 9,689 | 9,402 | 9,161 | 8,092 | 8,977 | 8,871 | 8,510 | 7,612 | 8,079 | |
International($M) | 6,310 | 6,405 | 6,555 | 6,074 | 6,161 | 6,041 | 5,781 | 5,355 | 5,709 | 5,980 | 5,950 | 5,643 | |
MEDTECH($M)2 | 8,642 | 8,926 | 8,636 | 8,801 | 8,430 | 8,541 | 8,020 | 8,188 | 7,891 | 7,957 | 7,821 | 7,673 | |
U.S.($M) | 4,512 | 4,554 | 4,459 | 4,506 | 4,306 | 4,383 | 4,213 | 4,227 | 4,038 | 4,059 | 4,008 | 3,930 | |
International($M) | 4,130 | 4,372 | 4,177 | 4,295 | 4,124 | 4,158 | 3,807 | 3,961 | 3,853 | 3,898 | 3,813 | 3,743 | |
U.S.($M) | 14,959 | 14,533 | 13,330 | 14,195 | 13,708 | 13,544 | 12,305 | 13,204 | 12,909 | 12,569 | 11,620 | 12,009 | |
International($M) | 10,440 | 10,777 | 10,732 | 10,369 | 10,285 | 10,199 | 9,588 | 9,316 | 9,562 | 9,878 | 9,763 | 9,386 | |
Europe($M) | 5,405 | 5,726 | 5,848 | 5,598 | 5,440 | 5,387 | 5,110 | 4,921 | 4,914 | 5,214 | 5,163 | 4,962 | |
Asia-Pacific, Africa($M) | 3,650 | 3,742 | 3,591 | 3,500 | 3,614 | 3,606 | 3,311 | 3,260 | 3,475 | 3,452 | 3,406 | 3,258 | |
Western Hemisphere, excluding U.S.($M) | 1,385 | 1,309 | 1,293 | 1,271 | 1,231 | 1,206 | 1,167 | 1,135 | 1,173 | 1,212 | 1,194 | 1,166 | |
Innovative Medicine($M) | 12,271 | 12,088 | 11,036 | 11,787 | 11,891 | 11,224 | 9,853 | 10,818 | 11,031 | 10,887 | 10,192 | ||
MEDTECH($M) | 5,045 | 5,189 | 4,935 | 4,828 | 4,818 | 4,903 | 4,694 | 4,592 | 4,510 | 4,709 | 4,701 | ||
Innovative Medicine($M) | 5,066 | 6,249 | 5,317 | 5,058 | 6,446 | 5,552 | 5,210 | 4,009 | 4,482 | 5,459 | 4,969 | ||
MEDTECH($M) | 776 | 1,177 | 1,239 | 201 | 1,287 | 1,204 | 1,421 | 72 | 1,059 | 1,089 | 1,520 | ||
MEDTECH($M) | -599 | -593 | -509 | -827 | -603 | -591 | -480 | -814 | -555 | -581 | -493 | ||
Innovative Medicine($M) | -704 | -653 | -508 | -910 | -479 | -411 | -276 | -739 | -418 | -321 | -232 | ||
MEDTECH($M) | 86,214 | 86,581 | 86,179 | 86,482 | 86,502 | 86,745 | 85,111 | 84,322 | 74,710 | ||||
Innovative Medicine($M) | 78,944 | 78,856 | 78,118 | 78,057 | 74,422 | 75,487 | 58,727 | 57,070 | 58,324 | ||||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)2 | |||||||||||||
Consolidated sales to customers ($M)($M)3 | 25,399 | 25,310 | 24,062 | 24,564 | 23,993 | 23,743 | 21,893 | 22,520 | 22,471 | 22,447 | 21,383 | 21,395 | |
Geographic sales — United States ($M)($M)1 | 14,959 | 14,533 | 13,330 | 14,195 | 13,708 | 13,544 | 12,305 | 13,204 | 12,909 | 12,569 | 11,620 | 12,009 | |
U.S. reported & operational sales growth YoY (%)(%) | 9.1% | 7.3% | 8.3% | 7.5% | 6.2% | 7.8% | 5.9% | 10.0% | 7.6% | 7.8% | 7.8% | 11.0% | |
Geographic sales — International ($M)($M)6 | 10,440 | 10,777 | 10,732 | 10,369 | 10,285 | 10,199 | 9,588 | 9,316 | 9,562 | 9,878 | 9,763 | 9,386 | |
Europe sales ($M)($M)3 | 5,405 | 5,726 | 5,848 | 5,598 | 5,440 | 5,387 | 5,110 | 4,921 | 4,914 | 5,214 | 5,163 | 4,962 | |
Europe reported sales growth YoY (%)(%) | -0.6% | 6.3% | 14.5% | 13.8% | 10.7% | 3.3% | -1.0% | -0.8% | 4.0% | 1.6% | -7.6% | -3.2% | |
Europe operational (constant-currency) sales growth YoY (%)(%) | 1.0% | 3.3% | 2.7% | 5.2% | 4.4% | -1.9% | 2.2% | -0.2% | 3.0% | 3.4% | -7.7% | -5.8% | |
Europe currency (FX) impact YoY (%)(%) | -1.6% | 3.0% | 11.8% | 8.6% | 6.3% | 5.2% | -3.2% | -0.6% | 1.0% | -1.8% | 0.1% | 2.6% | |
Western Hemisphere excluding U.S. sales ($M)($M)3 | 1,385 | 1,309 | 1,293 | 1,271 | 1,231 | 1,206 | 1,167 | 1,135 | 1,173 | 1,212 | 1,194 | 1,166 | |
Western Hemisphere ex-U.S. reported sales growth YoY (%)(%) | 12.5% | 8.5% | 10.8% | 12.0% | 4.9% | -0.5% | -2.3% | -2.7% | 0.3% | 6.7% | 11.0% | 14.0% | |
Western Hemisphere ex-U.S. operational sales growth YoY (%)(%) | 8.0% | 2.7% | 2.5% | 11.0% | 7.3% | 6.2% | 9.2% | 17.6% | 20.3% | 22.6% | 21.3% | 18.1% | |
Western Hemisphere ex-U.S. currency (FX) impact YoY (%)(%) | 4.5% | 5.8% | 8.3% | 1.0% | -2.4% | -6.7% | -11.5% | -20.3% | -20.0% | -15.9% | -10.3% | -4.1% | |
Asia-Pacific, Africa sales ($M)($M)3 | 3,650 | 3,742 | 3,591 | 3,500 | 3,614 | 3,606 | 3,311 | 3,260 | 3,475 | 3,452 | 3,406 | 3,258 | |
Asia-Pacific, Africa reported sales growth YoY (%)(%) | 1.0% | 3.8% | 8.5% | 7.4% | 4.0% | 4.4% | -2.8% | 0.1% | 0.5% | -4.0% | -1.1% | 9.7% | |
Asia-Pacific, Africa operational sales growth YoY (%)(%) | 1.0% | 3.9% | 6.1% | 7.2% | 3.4% | 2.4% | -0.6% | 0.9% | 1.5% | 1.9% | 5.0% | 12.1% | |
Asia-Pacific, Africa currency (FX) impact YoY (%)(%) | 0.0% | -0.1% | 2.4% | 0.2% | 0.6% | 2.0% | -2.2% | -0.8% | -1.0% | -5.9% | -6.1% | -2.4% | |
International reported sales growth YoY (%)(%) | 1.5% | 5.7% | 11.9% | 11.3% | 7.6% | 3.2% | -1.8% | -0.7% | 2.2% | 0.2% | -3.4% | 2.9% | |
International operational (constant-currency) sales growth YoY (%)(%) | 1.8% | 3.4% | 3.9% | 6.6% | 4.4% | 0.6% | 2.1% | 2.5% | 4.6% | 5.1% | -0.3% | 2.7% | |
International currency (FX) impact YoY (%)(%) | -0.3% | 2.3% | 8.0% | 4.7% | 3.2% | 2.6% | -3.9% | -3.2% | -2.4% | -4.9% | -3.1% | 0.2% | |
Worldwide reported sales growth YoY (%)(%)3 | 5.9% | 6.6% | 9.9% | 9.1% | 6.8% | 5.8% | 2.4% | 5.3% | 5.2% | 4.3% | 2.3% | 7.3% | |
Worldwide operational (constant-currency) sales growth YoY (%)(%) | 6.0% | 5.6% | 6.4% | 7.1% | 5.4% | 4.6% | 4.2% | 6.7% | 6.3% | 6.6% | 3.9% | 7.2% | |
Worldwide currency (FX) impact YoY (%)(%) | -0.1% | 1.0% | 3.5% | 2.0% | 1.4% | 1.2% | -1.8% | -1.4% | -1.1% | -2.3% | -1.6% | 0.1% | |
Worldwide adjusted operational sales growth ex-A&D YoY (%)(%) | 6.1% | 5.7% | 5.3% | 6.1% | 4.4% | 3.0% | 3.3% | 5.7% | 5.4% | 6.5% | 4.0% | 5.7% | |
Innovative Medicine Segment Total — Worldwide sales ($M)($M)7 | 16,757 | 16,384 | 15,426 | 15,763 | 15,563 | 15,202 | 13,873 | 14,332 | 14,580 | 14,490 | 13,562 | 13,722 | |
Innovative Medicine Segment Total — U.S. sales ($M)($M)1 | 10,447 | 9,979 | 8,871 | 9,689 | 9,402 | 9,161 | 8,092 | 8,977 | 8,871 | 8,510 | 7,612 | 8,079 | |
Innovative Medicine Segment Total — U.S. operational growth YoY (%)(%) | 11.1% | 8.9% | 9.6% | 7.9% | 6.0% | 7.6% | 6.3% | 11.1% | 7.5% | 8.9% | 8.4% | 9.5% | |
Innovative Medicine Segment Total — International sales ($M)($M)1 | 6,310 | 6,405 | 6,555 | 6,074 | 6,161 | 6,041 | 5,781 | 5,355 | 5,709 | 5,980 | 5,950 | 5,643 | |
Innovative Medicine Segment Total — International operational growth YoY (%)(%) | 3.0% | 3.6% | 4.3% | 7.9% | 4.3% | -1.6% | 1.5% | -1.0% | 4.4% | 6.4% | -4.0% | -3.1% | |
Innovative Medicine Segment Total — Worldwide reported growth YoY (%)(%) | 7.7% | 7.8% | 11.2% | 10.0% | 6.8% | 4.9% | 2.3% | 4.4% | 4.9% | 5.5% | 1.1% | 4.2% | |
Innovative Medicine Segment Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 7.9% | 6.8% | 7.4% | 7.9% | 5.3% | 3.8% | 4.2% | 6.1% | 6.3% | 7.8% | 2.5% | 4.0% | |
Innovative Medicine Segment Total — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 1.0% | 3.8% | 2.1% | 1.5% | 1.1% | -1.9% | -1.7% | -1.4% | -2.3% | -1.4% | 0.2% | |
Innovative Medicine — Worldwide adjusted operational growth ex-A&D YoY (%)(%) | 8.0% | 6.9% | 5.6% | 6.2% | 3.7% | 2.4% | 4.4% | 6.3% | 6.4% | 8.0% | 2.5% | 4.0% | |
Oncology Therapeutic Area Total — Worldwide sales ($M)($M)13 | 7,602 | 7,406 | 6,973 | 6,861 | 6,529 | 6,312 | 5,678 | 5,497 | 5,380 | 5,090 | 4,814 | 4,618 | |
Oncology Therapeutic Area Total — U.S. sales ($M)($M)1 | 4,267 | 4,069 | 3,615 | 3,793 | 3,468 | 3,385 | 3,013 | 3,019 | 2,816 | 2,636 | 2,383 | 2,285 | |
Oncology Therapeutic Area Total — U.S. operational growth YoY (%)(%) | 23.0% | 20.3% | 20.0% | 25.6% | 23.2% | 28.4% | 26.4% | 32.2% | 26.9% | 27.4% | 26.2% | 23.0% | |
Oncology Therapeutic Area Total — International sales ($M)($M)1 | 3,335 | 3,337 | 3,358 | 3,069 | 3,060 | 2,928 | 2,664 | 2,476 | 2,565 | 2,455 | 2,430 | 2,334 | |
Oncology Therapeutic Area Total — International operational growth YoY (%)(%) | 9.5% | 11.2% | 15.3% | 17.3% | 14.8% | 15.7% | 14.4% | 10.6% | 14.3% | 10.8% | 12.6% | 12.0% | |
Oncology Therapeutic Area Total — Worldwide reported growth YoY (%)(%) | 16.4% | 17.3% | 22.8% | 24.8% | 21.3% | 24.0% | 17.9% | 19.0% | 18.7% | 15.7% | 17.1% | 17.6% | |
Oncology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 16.7% | 16.1% | 17.8% | 21.9% | 19.2% | 22.3% | 20.4% | 21.3% | 20.5% | 18.6% | 18.8% | 17.2% | |
Oncology Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%) | -0.3% | 1.2% | 5.0% | 2.9% | 2.1% | 1.7% | -2.5% | -2.3% | -1.8% | -2.9% | -1.7% | 0.4% | |
DARZALEX (daratumumab) — Worldwide sales ($M)($M)4 | 4,239 | 4,207 | 3,964 | 3,903 | 3,672 | 3,539 | 3,237 | 3,084 | 3,016 | 2,878 | 2,692 | 2,550 | |
DARZALEX (daratumumab) — U.S. sales ($M)($M)1 | 2,528 | 2,435 | 2,208 | 2,332 | 2,088 | 2,017 | 1,829 | 1,799 | 1,684 | 1,641 | 1,464 | 1,395 | |
DARZALEX (daratumumab) — U.S. operational growth YoY (%)(%) | 21.1% | 20.7% | 20.7% | 29.6% | 24.0% | 23.0% | 24.9% | 28.9% | 23.0% | 24.2% | 22.9% | 22.5% | |
DARZALEX (daratumumab) — International sales ($M)($M)1 | 1,711 | 1,772 | 1,756 | 1,571 | 1,584 | 1,521 | 1,409 | 1,285 | 1,332 | 1,237 | 1,228 | 1,155 | |
DARZALEX (daratumumab) — International operational growth YoY (%)(%) | 8.5% | 13.5% | 14.0% | 16.2% | 14.7% | 19.6% | 19.8% | 17.0% | 22.8% | 17.9% | 19.0% | 21.8% | |
DARZALEX (daratumumab) — Worldwide reported growth YoY (%)(%) | 15.4% | 18.9% | 22.5% | 26.6% | 21.7% | 23.0% | 20.3% | 20.9% | 20.7% | 18.4% | 18.9% | 22.4% | |
DARZALEX (daratumumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 15.6% | 17.6% | 17.8% | 24.1% | 19.9% | 21.5% | 22.5% | 23.5% | 22.9% | 21.3% | 21.0% | 22.2% | |
DARZALEX (daratumumab) — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 1.3% | 4.7% | 2.5% | 1.8% | 1.5% | -2.2% | -2.6% | -2.2% | -2.9% | -2.1% | 0.2% | |
ERLEADA (apalutamide) — Worldwide sales ($M)($M)4 | 1,023 | 995 | 949 | 959 | 936 | 908 | 771 | 784 | 790 | 736 | 689 | 647 | |
ERLEADA (apalutamide) — U.S. sales ($M)($M)1 | 423 | 396 | 342 | 405 | 378 | 378 | 292 | 342 | 337 | 318 | 285 | 287 | |
ERLEADA (apalutamide) — U.S. operational growth YoY (%)(%) | 11.8% | 4.7% | 17.3% | 18.6% | 12.3% | 18.6% | 2.5% | 19.0% | 17.1% | 32.2% | 14.1% | 4.4% | |
ERLEADA (apalutamide) — International sales ($M)($M)1 | 600 | 599 | 607 | 554 | 558 | 530 | 479 | 442 | 453 | 418 | 404 | 361 | |
ERLEADA (apalutamide) — International operational growth YoY (%)(%) | 7.7% | 9.7% | 15.5% | 17.5% | 17.6% | 22.8% | 23.1% | 25.7% | 34.0% | 32.8% | 40.6% | 34.0% | |
ERLEADA (apalutamide) — Worldwide reported growth YoY (%)(%) | 9.4% | 9.5% | 23.1% | 22.4% | 18.4% | 23.4% | 11.9% | 20.9% | 25.4% | 29.8% | 27.0% | 19.8% | |
ERLEADA (apalutamide) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 9.4% | 7.6% | 16.2% | 18.0% | 15.3% | 21.0% | 14.6% | 22.7% | 26.3% | 32.5% | 28.4% | 19.0% | |
ERLEADA (apalutamide) — Worldwide currency (FX) impact YoY (%)(%) | 0.0% | 1.9% | 6.9% | 4.4% | 3.1% | 2.4% | -2.7% | -1.8% | -0.9% | -2.7% | -1.4% | 0.8% | |
CARVYKTI (ciltacabtagene autoleucel) — Worldwide sales ($M)($M)4 | 710 | 657 | 597 | 555 | 524 | 439 | 369 | 334 | 286 | 186 | 157 | 159 | |
CARVYKTI (ciltacabtagene autoleucel) — U.S. sales ($M)($M)1 | 472 | 472 | 433 | 420 | 396 | 358 | 318 | 304 | 258 | 167 | 140 | 145 | |
CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%)(%) | 19.4% | 31.7% | 36.2% | 38.2% | 53.3% | 84.9% | 46.5% | 99.8% | |||||
CARVYKTI (ciltacabtagene autoleucel) — International sales ($M)($M) | 238 | 185 | 164 | 135 | 128 | 81 | 51 | 31 | 27 | 20 | 16 | 13 | |
CARVYKTI (ciltacabtagene autoleucel) — Worldwide reported growth YoY (%)(%) | 35.5% | 49.4% | 62.1% | 65.8% | 83.5% | 87.7% | 59.8% | ||||||
CARVYKTI (ciltacabtagene autoleucel) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 35.2% | 47.7% | 57.4% | 63.2% | 81.4% | 87.6% | 59.9% | ||||||
CARVYKTI (ciltacabtagene autoleucel) — Worldwide currency (FX) impact YoY (%)(%) | 0.3% | 1.7% | 4.7% | 2.6% | 2.1% | 0.1% | -0.1% | ||||||
IMBRUVICA (ibrutinib) — Worldwide sales ($M)($M)4 | 563 | 599 | 660 | 684 | 695 | 735 | 709 | 731 | 753 | 770 | 784 | 788 | |
IMBRUVICA (ibrutinib) — U.S. sales ($M)($M)1 | 145 | 149 | 143 | 207 | 211 | 239 | 235 | 250 | 259 | 246 | 265 | 255 | |
IMBRUVICA (ibrutinib) — U.S. operational growth YoY (%)(%) | -31.6% | -37.6% | -39.1% | -17.4% | -18.3% | -2.7% | -11.5% | -2.0% | -1.9% | -6.4% | -1.5% | -19.8% | |
IMBRUVICA (ibrutinib) — International sales ($M)($M)1 | 420 | 449 | 517 | 478 | 483 | 496 | 474 | 481 | 494 | 525 | 518 | 533 | |
IMBRUVICA (ibrutinib) — International operational growth YoY (%)(%) | -12.6% | -11.8% | -1.4% | -7.5% | -6.6% | -8.4% | -4.2% | -6.8% | -7.2% | -5.6% | -5.6% | -3.8% | |
IMBRUVICA (ibrutinib) — Worldwide reported growth YoY (%)(%) | -18.8% | -18.6% | -6.9% | -6.5% | -7.8% | -4.5% | -9.5% | -7.2% | -6.8% | -8.5% | -5.2% | -8.9% | |
IMBRUVICA (ibrutinib) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -18.4% | -20.2% | -13.9% | -10.9% | -10.6% | -6.6% | -6.7% | -5.2% | -5.5% | -5.9% | -4.3% | -9.7% | |
IMBRUVICA (ibrutinib) — Worldwide currency (FX) impact YoY (%)(%) | -0.4% | 1.6% | 7.0% | 4.4% | 2.8% | 2.1% | -2.8% | -2.0% | -1.3% | -2.6% | -0.9% | 0.8% | |
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide sales ($M)($M)4 | 320 | 289 | 257 | 216 | 198 | 179 | 141 | 122 | 89 | 69 | 47 | ||
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. sales ($M)($M)1 | 201 | 190 | 175 | 146 | 136 | 139 | 113 | 101 | 68 | 52 | 36 | ||
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — U.S. operational growth YoY (%)(%) | 47.9% | 36.8% | 55.1% | 45.6% | 99.7% | 68.0% | |||||||
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — International sales ($M)($M) | 119 | 99 | 82 | 70 | 61 | 41 | 28 | 21 | 21 | 17 | 11 | ||
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide reported growth YoY (%)(%) | 62.3% | 60.8% | 82.7% | 78.0% | 69.0% | ||||||||
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 63.5% | 61.6% | 80.5% | 76.5% | 89.0% | ||||||||
RYBREVANT / LAZCLUZE (amivantamab / lazertinib) — Worldwide currency (FX) impact YoY (%)(%) | -1.2% | -0.8% | 2.2% | 1.5% | 122.0% | ||||||||
TECVAYLI (teclistamab) — Worldwide sales ($M)($M)4 | 312 | 260 | 202 | 176 | 177 | 166 | 151 | 146 | 135 | 135 | 133 | 126 | |
TECVAYLI (teclistamab) — U.S. sales ($M)($M) | 236 | 186 | 127 | 110 | 115 | 114 | 105 | 108 | 105 | 104 | 101 | 102 | |
TECVAYLI (teclistamab) — International sales ($M)($M)1 | 77 | 74 | 74 | 66 | 62 | 52 | 46 | 38 | 30 | 30 | 33 | 24 | |
TECVAYLI (teclistamab) — International operational growth YoY (%)(%) | 25.9% | 39.2% | 52.1% | 65.1% | 72.0% | 45.9% | 71.6% | 59.4% | 19.0% | ||||
TECVAYLI (teclistamab) — Worldwide reported growth YoY (%)(%) | 76.6% | 56.5% | 33.5% | 20.8% | 31.3% | 23.1% | 13.3% | 15.8% | 20.6% | 42.9% | 94.0% | ||
TECVAYLI (teclistamab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 77.3% | 56.1% | 30.1% | 18.9% | 29.9% | 22.4% | 15.0% | 18.0% | 21.4% | 43.5% | 112.0% | ||
TECVAYLI (teclistamab) — Worldwide currency (FX) impact YoY (%)(%) | -0.7% | 0.4% | 3.4% | 1.9% | 1.4% | 0.7% | -1.7% | -2.2% | -0.8% | -0.6% | 126.0% | ||
TALVEY (talquetamab) — Worldwide sales ($M)($M)4 | 171 | 174 | 152 | 149 | 122 | 106 | 86 | 85 | 75 | 69 | 58 | ||
TALVEY (talquetamab) — U.S. sales ($M)($M)1 | 112 | 112 | 101 | 105 | 85 | 82 | 68 | 68 | 64 | 59 | 50 | ||
TALVEY (talquetamab) — U.S. operational growth YoY (%)(%) | 31.6% | 36.2% | 48.5% | 53.8% | 34.2% | 38.0% | 35.2% | ||||||
TALVEY (talquetamab) — International sales ($M)($M) | 59 | 62 | 51 | 44 | 37 | 24 | 18 | 17 | 12 | 9 | 8 | ||
TALVEY (talquetamab) — Worldwide reported growth YoY (%)(%) | 40.9% | 63.3% | 76.7% | 75.8% | 60.8% | 55.0% | 48.4% | ||||||
TALVEY (talquetamab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 42.1% | 62.6% | 72.8% | 73.1% | 59.1% | 54.3% | 50.2% | ||||||
TALVEY (talquetamab) — Worldwide currency (FX) impact YoY (%)(%) | -1.2% | 0.7% | 3.9% | 2.7% | 1.7% | 0.7% | -1.8% | ||||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide sales ($M)($M)4 | 119 | 113 | 145 | 125 | 135 | 150 | 165 | 181 | 201 | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — U.S. sales ($M)($M)1 | 5 | 5 | 6 | 7 | 9 | 5 | 11 | 9 | 9 | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — U.S. operational growth YoY (%)(%) | -41.4% | -25.0% | -38.9% | -24.3% | -7.3% | -66.0% | 21.6% | -41.3% | -52.0% | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — International sales ($M)($M)1 | 115 | 108 | 139 | 118 | 127 | 144 | 154 | 172 | 191 | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — International operational growth YoY (%)(%) | -11.1% | -26.8% | -13.3% | -28.5% | -30.7% | -24.4% | -23.6% | -20.7% | -23.2% | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide reported growth YoY (%)(%) | -11.9% | -25.1% | -11.6% | -30.9% | -32.4% | -30.0% | -27.7% | -25.9% | -25.6% | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -13.0% | -26.8% | -14.9% | -28.3% | -29.6% | -27.5% | -21.9% | -22.1% | -25.3% | ||||
ZYTIGA (abiraterone acetate) [reported separately through FY2025Q4] — Worldwide currency (FX) impact YoY (%)(%) | 1.1% | 1.7% | 3.3% | -2.6% | -2.8% | -2.5% | -5.8% | -3.8% | -0.3% | ||||
Other Oncology medicines — Worldwide sales ($M)($M)4 | 262 | 226 | 192 | -283 | 207 | 238 | 214 | 75 | 86 | 83 | 73 | -8 | |
Other Oncology medicines — U.S. sales ($M)($M) | 149 | 131 | 85 | 43 | 61 | 56 | 54 | 39 | 36 | 37 | 33 | -32 | |
Other Oncology medicines — International sales ($M)($M)1 | 111 | 97 | 106 | -326 | 147 | 181 | 160 | 36 | 50 | 45 | 41 | 24 | |
Other Oncology medicines — International operational growth YoY (%)(%) | -23.9% | -45.7% | -36.3% | 3.0% | -25.6% | -12.3% | 10.1% | 30.6% | 27.6% | -6.0% | -5.6% | 28.4% | |
Other Oncology medicines — Worldwide reported growth YoY (%)(%) | 26.3% | -4.6% | -10.6% | 32.9% | 9.7% | 11.7% | 21.7% | 90.4% | 84.2% | 80.2% | |||
Other Oncology medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 26.7% | -3.9% | -12.5% | 30.3% | 7.7% | 9.7% | 24.7% | 92.4% | 87.2% | 80.5% | |||
Other Oncology medicines — Worldwide currency (FX) impact YoY (%)(%) | -0.4% | -0.7% | 1.9% | 2.6% | 2.0% | 2.0% | -3.0% | -2.0% | -3.0% | -0.3% | |||
Immunology Therapeutic Area Total — Worldwide sales ($M)($M)9 | 4,221 | 3,844 | 3,380 | 3,860 | 4,168 | 3,993 | 3,707 | 4,238 | 4,621 | 4,722 | 4,247 | 4,595 | |
Immunology Therapeutic Area Total — U.S. sales ($M)($M)1 | 2,804 | 2,372 | 1,855 | 2,495 | 2,676 | 2,505 | 2,196 | 2,856 | 3,068 | 2,978 | 2,453 | 3,033 | |
Immunology Therapeutic Area Total — U.S. operational growth YoY (%)(%) | 4.8% | -5.3% | -15.5% | -12.6% | -12.8% | -15.9% | -10.5% | -5.9% | -3.9% | 4.0% | 0.2% | 8.1% | |
Immunology Therapeutic Area Total — International sales ($M)($M)1 | 1,417 | 1,473 | 1,524 | 1,364 | 1,493 | 1,489 | 1,510 | 1,383 | 1,552 | 1,744 | 1,794 | 1,562 | |
Immunology Therapeutic Area Total — International operational growth YoY (%)(%) | -4.8% | -3.5% | -6.4% | -5.5% | -6.3% | -16.2% | -11.5% | -6.5% | -2.1% | 13.2% | 11.0% | 17.7% | |
Immunology Therapeutic Area Total — Worldwide reported growth YoY (%)(%) | 1.3% | -3.7% | -8.8% | -8.9% | -9.8% | -15.4% | -12.7% | -7.8% | -4.7% | 5.0% | 3.3% | 11.6% | |
Immunology Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 1.4% | -4.6% | -11.8% | -10.3% | -10.6% | -16.0% | -10.9% | -6.1% | -3.3% | 7.3% | 4.6% | 11.2% | |
Immunology Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%) | -0.1% | 0.9% | 3.0% | 1.4% | 0.8% | 0.6% | -1.8% | -1.7% | -1.4% | -2.3% | -1.3% | 0.4% | |
TREMFYA (guselkumab) — Worldwide sales ($M)($M)4 | 2,396 | 2,046 | 1,608 | 1,589 | 1,424 | 1,186 | 956 | 949 | 1,007 | 906 | 808 | 910 | |
TREMFYA (guselkumab) — U.S. sales ($M)($M)1 | 1,772 | 1,465 | 1,042 | 1,145 | 989 | 796 | 599 | 654 | 691 | 589 | 509 | 657 | |
TREMFYA (guselkumab) — U.S. operational growth YoY (%)(%) | 79.1% | 84.2% | 73.9% | 75.1% | 43.1% | 35.2% | 17.6% | -0.6% | 9.1% | 30.8% | 25.4% | 21.6% | |
TREMFYA (guselkumab) — International sales ($M)($M)1 | 624 | 581 | 566 | 445 | 434 | 391 | 356 | 295 | 316 | 317 | 299 | 252 | |
TREMFYA (guselkumab) — International operational growth YoY (%)(%) | 43.4% | 44.2% | 46.8% | 44.0% | 33.4% | 20.5% | 24.4% | 21.7% | 26.9% | 30.5% | 31.5% | 17.8% | |
TREMFYA (guselkumab) — Worldwide reported growth YoY (%)(%) | 68.3% | 72.5% | 68.3% | 67.6% | 41.3% | 31.0% | 18.2% | 4.2% | 13.0% | 28.3% | 26.3% | 21.0% | |
TREMFYA (guselkumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 68.2% | 71.0% | 63.8% | 65.4% | 40.1% | 30.1% | 20.1% | 5.6% | 14.3% | 30.7% | 27.6% | 20.5% | |
TREMFYA (guselkumab) — Worldwide currency (FX) impact YoY (%)(%) | 0.1% | 1.5% | 4.5% | 2.2% | 1.2% | 0.9% | -1.9% | -1.4% | -1.3% | -2.4% | -1.3% | 0.5% | |
STELARA (ustekinumab) — Worldwide sales ($M)($M)4 | 716 | 740 | 656 | 1,230 | 1,570 | 1,653 | 1,625 | 2,349 | 2,676 | 2,885 | 2,451 | 2,753 | |
STELARA (ustekinumab) — U.S. sales ($M)($M)1 | 368 | 336 | 220 | 766 | 1,022 | 1,078 | 981 | 1,699 | 1,770 | 1,855 | 1,396 | 1,786 | |
STELARA (ustekinumab) — U.S. operational growth YoY (%)(%) | -64.0% | -68.8% | -77.6% | -54.9% | -42.3% | -41.9% | -29.8% | -4.9% | -7.5% | 2.1% | -3.8% | 10.1% | |
STELARA (ustekinumab) — International sales ($M)($M)1 | 349 | 404 | 435 | 462 | 549 | 575 | 644 | 650 | 906 | 1,030 | 1,055 | 967 | |
STELARA (ustekinumab) — International operational growth YoY (%)(%) | -35.5% | -31.1% | -37.7% | -32.3% | -41.4% | -45.6% | -35.8% | -29.6% | -2.3% | 10.1% | 8.2% | 23.9% | |
STELARA (ustekinumab) — Worldwide reported growth YoY (%)(%) | -54.4% | -55.2% | -59.7% | -47.7% | -41.3% | -42.7% | -33.7% | -14.7% | -6.6% | 3.1% | 0.3% | 15.3% | |
STELARA (ustekinumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -54.0% | -55.7% | -61.7% | -48.6% | -42.0% | -43.2% | -32.3% | -13.6% | -5.7% | 4.9% | 1.1% | 14.5% | |
STELARA (ustekinumab) — Worldwide currency (FX) impact YoY (%)(%) | -0.4% | 0.5% | 2.0% | 0.9% | 0.7% | 0.5% | -1.4% | -1.1% | -0.9% | -1.8% | -0.8% | 0.8% | |
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide sales ($M)($M)4 | 568 | 618 | 647 | 632 | 687 | 690 | 659 | 583 | 516 | 537 | 554 | 502 | |
SIMPONI / SIMPONI ARIA (golimumab) — U.S. sales ($M)($M)1 | 269 | 260 | 269 | 287 | 309 | 305 | 292 | 262 | 299 | 267 | 254 | 258 | |
SIMPONI / SIMPONI ARIA (golimumab) — U.S. operational growth YoY (%)(%) | -13.2% | -14.6% | -7.8% | 9.6% | 3.6% | 14.0% | 14.8% | 1.3% | -3.7% | -6.3% | -6.2% | -7.8% | |
SIMPONI / SIMPONI ARIA (golimumab) — International sales ($M)($M)1 | 299 | 358 | 378 | 345 | 377 | 387 | 366 | 321 | 218 | 270 | 299 | 244 | |
SIMPONI / SIMPONI ARIA (golimumab) — International operational growth YoY (%)(%) | -20.3% | -9.5% | -4.1% | 3.7% | 69.8% | 40.8% | 29.7% | 44.2% | -23.3% | 22.8% | 20.0% | 11.8% | |
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide reported growth YoY (%)(%) | -17.3% | -10.5% | -1.7% | 8.4% | 32.9% | 28.6% | 18.9% | 16.2% | -18.0% | 1.6% | 3.0% | 0.1% | |
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -17.1% | -11.7% | -5.7% | 6.4% | 31.5% | 27.5% | 22.9% | 22.1% | -13.6% | 7.1% | 6.8% | 0.8% | |
SIMPONI / SIMPONI ARIA (golimumab) — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 1.2% | 4.0% | 2.0% | 1.4% | 1.1% | -4.0% | -5.9% | -4.4% | -5.5% | -3.8% | -0.7% | |
REMICADE (infliximab) — Worldwide sales ($M)($M)5 | 394 | 338 | 422 | 370 | 476 | 455 | 467 | 359 | 419 | 393 | 434 | 429 | |
REMICADE (infliximab) — U.S. sales ($M)($M)1 | 258 | 215 | 269 | 248 | 326 | 283 | 314 | 231 | 281 | 231 | 266 | 294 | |
REMICADE (infliximab) — U.S. operational growth YoY (%)(%) | -20.8% | -24.1% | -14.4% | 7.1% | 16.2% | 22.5% | 18.1% | -21.4% | -5.4% | -16.7% | -3.9% | -7.4% | |
REMICADE (infliximab) — U.S. Exports ($M)($M)1 | 12 | 10 | 18 | 11 | 19 | 34 | 10 | 9 | 27 | 35 | 27 | 35 | |
REMICADE (infliximab) — U.S. Exports growth YoY (%)(%) | -37.1% | -71.0% | 78.6% | 17.1% | -30.9% | -2.6% | -64.2% | -73.3% | -28.9% | 7.9% | -32.7% | -15.1% | |
REMICADE (infliximab) — International sales ($M)($M)1 | 124 | 112 | 136 | 110 | 132 | 138 | 143 | 117 | 112 | 127 | 141 | 100 | |
REMICADE (infliximab) — International operational growth YoY (%)(%) | -7.5% | -20.5% | -10.5% | -7.3% | 16.7% | 8.8% | 6.8% | 22.9% | -6.5% | -12.0% | -14.2% | -12.4% | |
REMICADE (infliximab) — Worldwide reported growth YoY (%)(%) | -17.3% | -25.8% | -9.5% | 3.2% | 13.6% | 15.9% | 7.5% | -16.5% | -9.1% | -14.9% | -10.9% | -9.6% | |
REMICADE (infliximab) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -17.6% | -26.4% | -11.2% | 2.6% | 13.3% | 15.9% | 9.3% | -15.0% | -7.7% | -13.4% | -9.9% | -9.4% | |
REMICADE (infliximab) — Worldwide currency (FX) impact YoY (%)(%) | 0.3% | 0.6% | 1.7% | 0.6% | 0.3% | 0.0% | -1.8% | -1.5% | -1.4% | -1.5% | -1.0% | -0.2% | |
Other Immunology medicines — Worldwide sales ($M)($M)2 | 147 | 104 | 46 | 40 | 12 | 8 | 1 | 0 | 1 | 2 | 0 | 2 | |
Other Immunology medicines — U.S. sales ($M)($M) | 126 | 85 | 38 | 38 | 12 | 8 | 1 | 0 | 1 | 2 | 0 | 2 | |
Other Immunology medicines — International sales ($M)($M) | 21 | 18 | 9 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Neuroscience Therapeutic Area Total — Worldwide sales ($M)($M)9 | 2,375 | 2,337 | 2,175 | 2,115 | 2,024 | 2,051 | 1,647 | 1,775 | 1,755 | 1,782 | 1,803 | 1,801 | |
Neuroscience Therapeutic Area Total — U.S. sales ($M)($M)1 | 1,733 | 1,659 | 1,494 | 1,439 | 1,367 | 1,377 | 968 | 1,148 | 1,094 | 1,102 | 1,054 | 1,022 | |
Neuroscience Therapeutic Area Total — U.S. operational growth YoY (%)(%) | 26.8% | 20.5% | 54.3% | 25.4% | 25.0% | 24.9% | -8.1% | 12.3% | 5.6% | 7.1% | |||
Neuroscience Therapeutic Area Total — International sales ($M)($M)1 | 642 | 678 | 681 | 675 | 658 | 674 | 679 | 628 | 662 | 679 | 749 | 780 | |
Neuroscience Therapeutic Area Total — International operational growth YoY (%)(%) | -1.7% | -1.1% | -6.3% | 4.3% | -2.6% | -2.6% | -5.5% | -16.8% | -3.9% | -6.0% | -4.4% | -2.0% | |
Neuroscience Therapeutic Area Total — Worldwide reported growth YoY (%)(%) | 17.3% | 14.0% | 32.0% | 19.1% | 15.3% | 15.1% | -8.6% | -1.5% | 0.8% | -0.6% | 0.0% | 3.7% | |
Neuroscience Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 17.6% | 13.4% | 29.3% | 17.9% | 14.6% | 14.4% | -7.0% | -0.3% | 1.7% | 1.5% | 2.2% | 5.4% | |
Neuroscience Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%) | -0.3% | 0.6% | 2.7% | 1.2% | 0.7% | 0.7% | -1.6% | -1.2% | -0.9% | -2.1% | -2.2% | -1.7% | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide sales ($M)($M)4 | 998 | 1,015 | 1,038 | 986 | 929 | 992 | 903 | 1,063 | 1,049 | 1,054 | 1,056 | 1,011 | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. sales ($M)($M)1 | 739 | 738 | 758 | 704 | 664 | 732 | 625 | 796 | 780 | 784 | 765 | 733 | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — U.S. operational growth YoY (%)(%) | 11.4% | 0.8% | 21.2% | -11.5% | -14.9% | -6.7% | -18.2% | 8.6% | 6.8% | 8.8% | 7.2% | 8.0% | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — International sales ($M)($M)1 | 258 | 278 | 280 | 281 | 267 | 260 | 277 | 267 | 269 | 269 | 292 | 278 | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — International operational growth YoY (%)(%) | -2.4% | 5.1% | -4.9% | 1.9% | -3.0% | -5.1% | -1.1% | -1.8% | -8.3% | -9.0% | -8.7% | -15.7% | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide reported growth YoY (%)(%) | 7.3% | 2.3% | 15.0% | -7.3% | -11.3% | -5.9% | -14.5% | 5.1% | 1.9% | 2.2% | 1.2% | 0.3% | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 7.5% | 1.9% | 13.2% | -8.2% | -11.9% | -6.3% | -13.5% | 5.7% | 2.4% | 3.5% | 2.2% | 0.3% | |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA (paliperidone palmitate) — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 0.4% | 1.8% | 0.9% | 0.6% | 0.4% | -1.0% | -0.6% | -0.5% | -1.3% | -1.0% | 0.0% | |
SPRAVATO (esketamine) — Worldwide sales ($M)($M)4 | 624 | 584 | 468 | 503 | 459 | 414 | 320 | 297 | 284 | 271 | 225 | 206 | |
SPRAVATO (esketamine) — U.S. sales ($M)($M)1 | 559 | 514 | 406 | 438 | 405 | 366 | 276 | 269 | 243 | 226 | 191 | 180 | |
SPRAVATO (esketamine) — U.S. operational growth YoY (%)(%) | 37.9% | 40.7% | 47.0% | 63.0% | 67.1% | 61.1% | 45.0% | 50.1% | 56.8% | 57.9% | 71.5% | 72.3% | |
SPRAVATO (esketamine) — International sales ($M)($M)1 | 66 | 70 | 61 | 64 | 53 | 50 | 43 | 28 | 42 | 44 | 34 | 26 | |
SPRAVATO (esketamine) — International operational growth YoY (%)(%) | 21.4% | 34.7% | 28.7% | 23.8% | 11.0% | 31.7% | 12.5% | 47.4% | 77.4% | 74.8% | 83.4% | ||
SPRAVATO (esketamine) — Worldwide reported growth YoY (%)(%) | 36.1% | 40.8% | 46.4% | 69.0% | 61.5% | 53.3% | 41.9% | 44.6% | 54.9% | 60.2% | 72.2% | 74.1% | |
SPRAVATO (esketamine) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 36.0% | 40.0% | 44.5% | 67.8% | 60.8% | 53.0% | 42.9% | 45.3% | 55.3% | 60.8% | 72.0% | 73.6% | |
SPRAVATO (esketamine) — Worldwide currency (FX) impact YoY (%)(%) | 0.1% | 0.8% | 1.9% | 1.2% | 0.7% | 0.3% | -1.0% | -0.7% | -0.4% | -0.6% | 0.2% | 0.5% | |
CAPLYTA (lumateperone) — Worldwide sales ($M)($M)2 | 398 | 361 | 270 | 249 | 240 | 211 | 0 | 0 | 0 | 0 | |||
CAPLYTA (lumateperone) — U.S. sales ($M)($M) | 398 | 361 | 270 | 249 | 240 | 211 | 0 | 0 | 0 | 0 | |||
CAPLYTA (lumateperone) — International sales ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
CONCERTA / methylphenidate — Worldwide sales ($M)($M)4 | 143 | 146 | 136 | 132 | 140 | 164 | 148 | 159 | 142 | 163 | 177 | 180 | |
CONCERTA / methylphenidate — U.S. sales ($M)($M)1 | 6 | 12 | 22 | 6 | 14 | 24 | 38 | 33 | 26 | 34 | 41 | 39 | |
CONCERTA / methylphenidate — U.S. operational growth YoY (%)(%) | -56.3% | -48.6% | -43.4% | -79.6% | -49.2% | -27.7% | -7.4% | -12.8% | -55.0% | -47.7% | -41.2% | 5.7% | |
CONCERTA / methylphenidate — International sales ($M)($M)1 | 138 | 133 | 115 | 126 | 127 | 139 | 110 | 125 | 117 | 129 | 136 | 142 | |
CONCERTA / methylphenidate — International operational growth YoY (%)(%) | 8.9% | -4.8% | -0.6% | -1.4% | 8.5% | 7.0% | -15.2% | -7.7% | -8.5% | -4.6% | 4.5% | 9.2% | |
CONCERTA / methylphenidate — Worldwide reported growth YoY (%)(%) | 2.1% | -10.8% | -8.0% | -17.1% | -1.4% | 0.2% | -16.3% | -11.7% | -24.8% | -21.5% | -14.1% | 7.4% | |
CONCERTA / methylphenidate — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 2.9% | -11.3% | -11.7% | -17.8% | -1.8% | -0.2% | -13.4% | -8.8% | -22.5% | -17.9% | -11.1% | 8.5% | |
CONCERTA / methylphenidate — Worldwide currency (FX) impact YoY (%)(%) | -0.8% | 0.5% | 3.7% | 0.7% | 0.4% | 0.4% | -2.9% | -2.9% | -2.3% | -3.6% | -3.0% | -1.1% | |
Other Neuroscience medicines — Worldwide sales ($M)($M)4 | 212 | 232 | 262 | 245 | 256 | 270 | 277 | 255 | 281 | 294 | 345 | 404 | |
Other Neuroscience medicines — U.S. sales ($M)($M)1 | 32 | 34 | 38 | 40 | 46 | 45 | 28 | 49 | 46 | 57 | 58 | 71 | |
Other Neuroscience medicines — U.S. operational growth YoY (%)(%) | -30.6% | -22.9% | 32.6% | -18.3% | 0.4% | -23.5% | -50.6% | -31.0% | -51.4% | -42.5% | -31.1% | -23.0% | |
Other Neuroscience medicines — International sales ($M)($M)1 | 180 | 198 | 224 | 205 | 210 | 226 | 248 | 206 | 235 | 237 | 287 | 334 | |
Other Neuroscience medicines — International operational growth YoY (%)(%) | -13.1% | -13.7% | -16.3% | -4.3% | -12.3% | -7.6% | -9.8% | -35.4% | -2.0% | -10.8% | -8.4% | 3.2% | |
Other Neuroscience medicines — Worldwide reported growth YoY (%)(%) | -17.3% | -14.0% | -5.4% | -4.1% | -8.9% | -8.4% | -19.6% | -36.9% | -17.4% | -23.7% | -18.5% | -8.7% | |
Other Neuroscience medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -16.2% | -15.2% | -11.3% | -6.9% | -10.2% | -10.7% | -16.7% | -34.6% | -15.7% | -19.1% | -12.9% | -2.3% | |
Other Neuroscience medicines — Worldwide currency (FX) impact YoY (%)(%) | -1.1% | 1.2% | 5.9% | 2.8% | 1.3% | 2.3% | -2.9% | -2.3% | -1.7% | -4.6% | -5.6% | -6.4% | |
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M)($M)7 | 897 | 1,143 | 1,135 | 1,184 | 1,115 | 1,113 | 1,025 | 1,092 | 1,102 | 1,039 | 1,049 | 1,017 | |
Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. sales ($M)($M)1 | 588 | 814 | 831 | 865 | 815 | 799 | 744 | 819 | 815 | 743 | 766 | 733 | |
Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. operational growth YoY (%)(%) | -27.8% | 1.8% | 11.7% | 5.7% | -0.1% | 7.6% | -2.9% | 11.6% | 20.0% | 8.7% | 27.5% | 20.2% | |
Pulmonary Hypertension (PH) Therapeutic Area Total — International sales ($M)($M)1 | 309 | 329 | 304 | 319 | 300 | 314 | 281 | 274 | 287 | 296 | 283 | 282 | |
Pulmonary Hypertension (PH) Therapeutic Area Total — International operational growth YoY (%)(%) | 4.1% | 3.4% | 1.0% | 12.2% | 2.0% | 2.8% | 3.2% | 1.2% | 9.7% | 11.2% | 10.9% | 10.9% | |
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide reported growth YoY (%)(%) | -19.5% | 2.6% | 10.7% | 8.4% | 1.1% | 7.1% | -2.3% | 7.4% | 15.6% | 6.9% | 20.2% | 16.7% | |
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -19.2% | 2.2% | 8.7% | 7.4% | 0.4% | 6.2% | -1.2% | 8.7% | 17.0% | 9.4% | 22.4% | 17.4% | |
Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%) | -0.3% | 0.4% | 2.0% | 1.0% | 0.7% | 0.9% | -1.1% | -1.3% | -1.4% | -2.5% | -2.2% | -0.7% | |
UPTRAVI (selexipag) — Worldwide sales ($M)($M)4 | 483 | 494 | 483 | 491 | 484 | 476 | 451 | 465 | 458 | 426 | 468 | 419 | |
UPTRAVI (selexipag) — U.S. sales ($M)($M)1 | 383 | 386 | 385 | 397 | 392 | 382 | 365 | 391 | 379 | 349 | 392 | 348 | |
UPTRAVI (selexipag) — U.S. operational growth YoY (%)(%) | -2.2% | 1.0% | 5.4% | 1.6% | 3.5% | 9.4% | -6.9% | 12.3% | 12.7% | 3.3% | 29.0% | 24.3% | |
UPTRAVI (selexipag) — International sales ($M)($M)1 | 100 | 108 | 98 | 94 | 92 | 94 | 86 | 75 | 80 | 76 | 76 | 70 | |
UPTRAVI (selexipag) — International operational growth YoY (%)(%) | 8.4% | 10.1% | 5.1% | 20.8% | 12.0% | 19.8% | 17.5% | 11.2% | 28.2% | 34.4% | 38.6% | 31.4% | |
UPTRAVI (selexipag) — Worldwide reported growth YoY (%)(%) | -0.1% | 3.8% | 7.1% | 5.7% | 5.6% | 11.7% | -3.6% | 11.2% | 14.2% | 6.6% | 29.2% | 24.6% | |
UPTRAVI (selexipag) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -0.2% | 2.8% | 5.4% | 4.7% | 5.0% | 11.3% | -2.9% | 12.1% | 15.2% | 8.1% | 30.5% | 25.4% | |
UPTRAVI (selexipag) — Worldwide currency (FX) impact YoY (%)(%) | 0.1% | 1.0% | 1.7% | 1.0% | 0.6% | 0.4% | -0.7% | -0.9% | -1.0% | -1.5% | -1.3% | -0.8% | |
OPSUMIT / OPSYNVI (macitentan) — Worldwide sales ($M)($M)4 | 372 | 602 | 606 | 643 | 578 | 582 | 522 | 570 | 583 | 548 | 524 | 536 | |
OPSUMIT / OPSYNVI (macitentan) — U.S. sales ($M)($M)1 | 193 | 416 | 433 | 458 | 409 | 403 | 363 | 408 | 417 | 376 | 356 | 368 | |
OPSUMIT / OPSYNVI (macitentan) — U.S. operational growth YoY (%)(%) | -52.8% | 3.2% | 19.3% | 11.9% | -1.6% | 6.9% | 2.1% | 4.8% | 25.4% | 13.7% | 30.4% | 20.5% | |
OPSUMIT / OPSYNVI (macitentan) — International sales ($M)($M)1 | 179 | 187 | 172 | 185 | 168 | 180 | 159 | 162 | 166 | 171 | 169 | 169 | |
OPSUMIT / OPSYNVI (macitentan) — International operational growth YoY (%)(%) | 7.8% | 3.6% | 1.7% | 10.9% | -1.8% | 2.1% | -2.5% | -2.5% | 1.7% | 0.5% | 4.6% | 8.3% | |
OPSUMIT / OPSYNVI (macitentan) — Worldwide reported growth YoY (%)(%) | -35.7% | 3.4% | 16.1% | 12.7% | -0.8% | 6.4% | -0.5% | 1.7% | 16.8% | 7.1% | 19.1% | 16.2% | |
OPSUMIT / OPSYNVI (macitentan) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -35.2% | 3.3% | 14.0% | 11.6% | -1.7% | 5.4% | 0.6% | 2.5% | 17.4% | 9.1% | 20.6% | 16.3% | |
OPSUMIT / OPSYNVI (macitentan) — Worldwide currency (FX) impact YoY (%)(%) | -0.5% | 0.1% | 2.1% | 1.1% | 0.9% | 1.0% | -1.1% | -0.8% | -0.6% | -2.0% | -1.5% | -0.1% | |
Other Pulmonary Hypertension medicines — Worldwide sales ($M)($M)4 | 42 | 47 | 46 | 49 | 53 | 55 | 52 | 57 | 60 | 67 | 56 | 61 | |
Other Pulmonary Hypertension medicines — U.S. sales ($M)($M)1 | 12 | 13 | 12 | 10 | 13 | 16 | 15 | 19 | 21 | 17 | 18 | 18 | |
Other Pulmonary Hypertension medicines — U.S. operational growth YoY (%)(%) | -7.3% | -16.9% | -21.1% | -43.7% | -36.5% | -12.4% | -12.7% | 54.0% | 18.8% | -24.6% | -29.4% | ||
Other Pulmonary Hypertension medicines — International sales ($M)($M)1 | 30 | 34 | 34 | 39 | 39 | 40 | 37 | 38 | 39 | 49 | 39 | 45 | |
Other Pulmonary Hypertension medicines — International operational growth YoY (%)(%) | -21.2% | -12.7% | -11.8% | 1.2% | -2.5% | -21.3% | -0.3% | -0.4% | 12.4% | 21.0% | -1.0% | -3.9% | |
Other Pulmonary Hypertension medicines — Worldwide reported growth YoY (%)(%) | -19.7% | -15.0% | -12.1% | -12.5% | -13.1% | -16.9% | -7.2% | 32.3% | 15.0% | 7.2% | -19.5% | -16.2% | |
Other Pulmonary Hypertension medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -17.7% | -13.9% | -14.5% | -13.5% | -14.1% | -19.0% | -4.3% | 39.3% | 25.9% | 20.4% | -8.9% | -12.4% | |
Other Pulmonary Hypertension medicines — Worldwide currency (FX) impact YoY (%)(%) | -2.0% | -1.1% | 2.4% | 1.0% | 1.0% | 2.1% | -2.9% | -7.0% | -10.9% | -13.2% | -10.6% | -3.8% | |
Infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M)($M)8 | 813 | 763 | 889 | 807 | 829 | 803 | 802 | 774 | 836 | 965 | 821 | 852 | |
Infectious Diseases (ID) Therapeutic Area Total — U.S. sales ($M)($M)1 | 317 | 300 | 342 | 303 | 326 | 320 | 315 | 331 | 365 | 334 | 324 | 353 | |
Infectious Diseases (ID) Therapeutic Area Total — U.S. operational growth YoY (%)(%) | -2.7% | -6.3% | 8.6% | -8.5% | -10.5% | -4.3% | -2.8% | -6.4% | 1.5% | -15.4% | -17.4% | -14.6% | |
Infectious Diseases (ID) Therapeutic Area Total — International sales ($M)($M)1 | 496 | 463 | 547 | 505 | 501 | 484 | 487 | 443 | 471 | 631 | 497 | 498 | |
Infectious Diseases (ID) Therapeutic Area Total — International operational growth YoY (%)(%) | -0.1% | -6.2% | 1.3% | 5.6% | 0.5% | -26.8% | 1.9% | -9.8% | -5.1% | -11.6% | -58.5% | -58.2% | |
Infectious Diseases (ID) Therapeutic Area Total — Worldwide reported growth YoY (%)(%) | -1.8% | -5.0% | 10.8% | 4.3% | -0.9% | -16.8% | -2.2% | -9.2% | -2.7% | -13.9% | -48.3% | -44.7% | |
Infectious Diseases (ID) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -1.1% | -6.3% | 4.1% | -0.4% | -4.3% | -19.0% | 0.1% | -8.4% | -2.4% | -12.9% | -48.3% | -46.5% | |
Infectious Diseases (ID) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%) | -0.7% | 1.3% | 6.7% | 4.7% | 3.4% | 2.2% | -2.3% | -0.8% | -0.3% | -1.0% | 0.0% | 1.8% | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide sales ($M)($M)4 | 381 | 372 | 443 | 383 | 397 | 396 | 403 | 407 | 449 | 438 | 418 | 439 | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. sales ($M)($M)1 | 307 | 296 | 334 | 294 | 315 | 312 | 305 | 321 | 355 | 321 | 314 | 341 | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — U.S. operational growth YoY (%)(%) | -2.5% | -5.1% | 9.5% | -8.4% | -11.0% | -3.0% | -2.9% | -5.8% | 2.8% | -16.0% | -16.9% | -14.4% | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International sales ($M)($M)1 | 74 | 76 | 109 | 89 | 81 | 85 | 98 | 86 | 94 | 117 | 104 | 98 | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — International operational growth YoY (%)(%) | -7.7% | -12.8% | 0.7% | -2.9% | -18.5% | -29.4% | -0.6% | -8.9% | -3.0% | 9.9% | 5.5% | -0.8% | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide reported growth YoY (%)(%) | -3.8% | -6.3% | 10.0% | -5.8% | -11.6% | -9.4% | -3.7% | -7.4% | 0.6% | -11.0% | -12.3% | -11.0% | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -3.6% | -6.8% | 7.4% | -7.2% | -12.6% | -10.0% | -2.3% | -6.5% | 1.5% | -10.3% | -12.3% | -11.8% | |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA (darunavir) — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 0.5% | 2.6% | 1.4% | 1.0% | 0.6% | -1.4% | -0.9% | -0.9% | -0.7% | 0.0% | 0.8% | |
EDURANT / rilpivirine — Worldwide sales ($M)($M)4 | 386 | 350 | 409 | 383 | 385 | 360 | 358 | 322 | 330 | 297 | 323 | 307 | |
EDURANT / rilpivirine — U.S. sales ($M)($M)1 | 5 | 3 | 7 | 5 | 7 | 6 | 8 | 7 | 8 | 8 | 8 | 9 | |
EDURANT / rilpivirine — U.S. operational growth YoY (%)(%) | -31.6% | -49.6% | -13.1% | -39.1% | -7.9% | -25.4% | -1.3% | -10.1% | -15.8% | -2.8% | -10.9% | -12.4% | |
EDURANT / rilpivirine — International sales ($M)($M)1 | 382 | 347 | 402 | 379 | 378 | 354 | 350 | 315 | 323 | 288 | 315 | 299 | |
EDURANT / rilpivirine — International operational growth YoY (%)(%) | 2.4% | -3.8% | 3.2% | 11.1% | 9.9% | 16.7% | 14.7% | 5.6% | 11.4% | 13.0% | 15.7% | 1.5% | |
EDURANT / rilpivirine — Worldwide reported growth YoY (%)(%) | 0.4% | -2.7% | 14.1% | 19.2% | 16.4% | 21.6% | 10.7% | 4.6% | 11.5% | 11.0% | 15.7% | 5.8% | |
EDURANT / rilpivirine — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 1.8% | -4.6% | 2.8% | 9.9% | 9.5% | 15.5% | 14.3% | 5.1% | 10.6% | 12.5% | 14.8% | 1.0% | |
EDURANT / rilpivirine — Worldwide currency (FX) impact YoY (%)(%) | -1.4% | 1.9% | 11.3% | 9.3% | 6.9% | 6.1% | -3.6% | -0.5% | 0.9% | -1.5% | 0.9% | 4.8% | |
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide sales ($M)($M)4 | 0 | 1 | 172 | 25 | 44 | ||||||||
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — U.S. sales ($M)($M) | 0 | 0 | 0 | 0 | 0 | ||||||||
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International sales ($M)($M)1 | 0 | 1 | 172 | 25 | 44 | ||||||||
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — International operational growth YoY (%)(%) | -98.9% | -39.7% | -96.7% | -95.2% | |||||||||
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%)(%) | -97.7% | -39.7% | -96.6% | -93.7% | |||||||||
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -98.9% | -39.7% | -96.7% | -95.2% | |||||||||
COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide currency (FX) impact YoY (%)(%) | 1.2% | 0.0% | 0.1% | 1.5% | |||||||||
Other Infectious Diseases medicines — Worldwide sales ($M)($M)4 | 46 | 41 | 37 | 40 | 47 | 47 | 41 | 45 | 56 | 233 | 78 | 1,179 | |
Other Infectious Diseases medicines — U.S. sales ($M)($M)1 | 5 | 1 | 1 | 4 | 4 | 2 | 2 | 1 | 3 | 5 | 2 | 4 | |
Other Infectious Diseases medicines — U.S. operational growth YoY (%)(%) | 29.9% | -47.9% | -56.9% | 92.9% | 57.3% | -51.8% | 7.7% | -53.1% | -52.2% | 18.5% | -68.8% | -30.4% | |
Other Infectious Diseases medicines — International sales ($M)($M)1 | 40 | 40 | 36 | 37 | 42 | 45 | 39 | 43 | 54 | 227 | 77 | 1,175 | |
Other Infectious Diseases medicines — International operational growth YoY (%)(%) | -7.9% | -12.8% | -14.7% | -18.0% | -22.3% | -80.6% | -47.0% | -22.4% | -20.5% | -21.1% | -30.6% | -4.9% | |
Other Infectious Diseases medicines — Worldwide reported growth YoY (%)(%) | -3.0% | -11.6% | -10.4% | -9.9% | -17.5% | -79.8% | -47.6% | -26.1% | -25.4% | -23.1% | -35.1% | -7.8% | |
Other Infectious Diseases medicines — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -4.5% | -14.6% | -16.5% | -13.2% | -18.5% | -79.9% | -45.9% | -24.4% | -22.9% | -18.8% | -33.1% | -7.1% | |
Other Infectious Diseases medicines — Worldwide currency (FX) impact YoY (%)(%) | 1.5% | 3.0% | 6.1% | 3.3% | 1.0% | 0.1% | -1.7% | -1.7% | -2.5% | -4.3% | -2.0% | -0.7% | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide sales ($M)($M)6 | 849 | 889 | 876 | 936 | 899 | 930 | 1,013 | 957 | 884 | 892 | 829 | 837 | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. sales ($M)($M)1 | 736 | 765 | 734 | 794 | 750 | 776 | 855 | 805 | 713 | 717 | 631 | 652 | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — U.S. operational growth YoY (%)(%) | -1.9% | -1.3% | -14.2% | -1.4% | 5.3% | 8.2% | 35.4% | 23.3% | -6.5% | -7.7% | -11.7% | -15.9% | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International sales ($M)($M)1 | 112 | 124 | 142 | 142 | 149 | 154 | 158 | 153 | 170 | 176 | 197 | 185 | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — International operational growth YoY (%)(%) | -23.8% | -21.5% | -17.5% | -10.7% | -15.6% | -13.2% | -15.3% | -15.1% | -10.0% | 4.0% | -6.8% | -6.7% | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide reported growth YoY (%)(%) | -5.6% | -4.3% | -13.6% | -2.2% | 1.7% | 4.2% | 22.3% | 14.3% | -7.6% | -6.2% | -10.6% | -13.7% | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -5.5% | -4.7% | -14.7% | -2.9% | 1.2% | 4.0% | 23.4% | 14.8% | -7.2% | -5.5% | -10.5% | -14.1% | |
Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide currency (FX) impact YoY (%)(%) | -0.1% | 0.4% | 1.1% | 0.7% | 0.5% | 0.2% | -1.1% | -0.5% | -0.4% | -0.7% | -0.1% | 0.4% | |
XARELTO (rivaroxaban) — Worldwide sales ($M)($M)4 | 653 | 664 | 642 | 687 | 635 | 621 | 690 | 676 | 592 | 587 | 518 | 525 | |
XARELTO (rivaroxaban) — U.S. sales ($M)($M)1 | 653 | 664 | 642 | 687 | 635 | 621 | 690 | 676 | 592 | 587 | 518 | 525 | |
XARELTO (rivaroxaban) — U.S. operational growth YoY (%)(%) | 2.7% | 7.1% | -7.0% | 1.7% | 7.4% | 5.6% | 33.3% | 28.5% | -5.2% | -7.9% | -10.4% | -21.2% | |
XARELTO (rivaroxaban) — International sales ($M)($M)1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
XARELTO (rivaroxaban) — International operational growth YoY (%)(%) | -23.8% | -21.5% | -17.5% | -10.7% | -15.6% | -13.2% | -15.3% | -15.1% | -10.0% | 4.0% | -6.8% | -6.7% | |
XARELTO (rivaroxaban) — Worldwide reported growth YoY (%)(%) | 2.7% | 7.1% | -7.0% | 1.7% | 7.4% | 5.6% | 33.3% | 28.5% | -5.2% | -7.9% | -10.4% | -21.2% | |
XARELTO (rivaroxaban) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 2.7% | 7.1% | -7.0% | 1.7% | 7.4% | 5.6% | 33.3% | 28.5% | -5.2% | -7.9% | -10.4% | -21.2% | |
XARELTO (rivaroxaban) — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 1.1% | 3.4% | 2.4% | 1.5% | 0.5% | -2.8% | -1.5% | -1.1% | -1.9% | -0.1% | 1.3% | |
Other Cardiovascular / Metabolism / Other medicines — Worldwide sales ($M)($M)2 | 197 | 225 | 233 | 249 | 264 | 309 | 323 | 281 | 292 | 305 | 311 | 312 | |
Other Cardiovascular / Metabolism / Other medicines — U.S. sales ($M)($M) | 84 | 101 | 91 | 107 | 115 | 155 | 165 | 130 | 121 | 129 | 114 | 127 | |
Other Cardiovascular / Metabolism / Other medicines — International sales ($M)($M) | 112 | 124 | 142 | 142 | 149 | 154 | 158 | 153 | 170 | 176 | 197 | 185 | |
MedTech Segment Total — Worldwide sales ($M)($M)9 | 8,642 | 8,926 | 8,636 | 8,801 | 8,430 | 8,541 | 8,020 | 8,188 | 7,891 | 7,957 | 7,821 | 7,673 | |
MedTech Segment Total — U.S. sales ($M)($M)1 | 4,512 | 4,554 | 4,459 | 4,506 | 4,306 | 4,383 | 4,213 | 4,227 | 4,038 | 4,059 | 4,008 | 3,930 | |
MedTech Segment Total — U.S. operational growth YoY (%)(%) | 4.8% | 3.9% | 5.9% | 6.6% | 6.6% | 8.0% | 5.1% | 7.6% | 7.8% | 5.7% | 6.6% | 14.1% | |
MedTech Segment Total — International sales ($M)($M)1 | 4,130 | 4,372 | 4,177 | 4,295 | 4,124 | 4,158 | 3,807 | 3,961 | 3,853 | 3,898 | 3,813 | 3,743 | |
MedTech Segment Total — International operational growth YoY (%)(%) | 0.1% | 3.2% | 3.2% | 4.9% | 4.5% | 4.1% | 3.0% | 7.6% | 5.0% | 3.2% | 6.1% | 12.8% | |
MedTech Segment Total — Worldwide reported growth YoY (%)(%) | 2.5% | 4.5% | 7.7% | 7.5% | 6.8% | 7.3% | 2.5% | 6.7% | 5.8% | 2.2% | 4.5% | 13.3% | |
MedTech Segment Total — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 2.5% | 3.6% | 4.6% | 5.8% | 5.6% | 6.1% | 4.1% | 7.6% | 6.4% | 4.4% | 6.3% | 13.4% | |
MedTech Segment Total — Worldwide currency (FX) impact YoY (%)(%) | 0.0% | 0.9% | 3.1% | 1.7% | 1.2% | 1.2% | -1.6% | -0.9% | -0.6% | -2.2% | -1.8% | -0.1% | |
MedTech — Worldwide adjusted operational growth ex-A&D YoY (%)(%) | 2.5% | 3.7% | 4.7% | 5.9% | 5.7% | 4.1% | 1.3% | 4.6% | 3.7% | 4.0% | 6.5% | 9.1% | |
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide sales ($M)($M)8 | 2,307 | 2,404 | 2,377 | 2,299 | 2,213 | 2,313 | 2,103 | 2,062 | 1,966 | 1,873 | 1,806 | 1,669 | |
Cardiovascular (formerly Interventional Solutions) Franchise — U.S. sales ($M)($M)1 | 1,397 | 1,426 | 1,399 | 1,374 | 1,306 | 1,364 | 1,261 | 1,221 | 1,148 | 1,119 | 1,025 | 971 | |
Cardiovascular (formerly Interventional Solutions) Franchise — U.S. operational growth YoY (%)(%) | 7.0% | 4.5% | 10.9% | 12.5% | 13.8% | 21.9% | 23.0% | 25.8% | 28.6% | 23.3% | 18.8% | 61.0% | |
Cardiovascular (formerly Interventional Solutions) Franchise — International sales ($M)($M)1 | 910 | 978 | 978 | 925 | 908 | 948 | 842 | 841 | 819 | 753 | 781 | 698 | |
Cardiovascular (formerly Interventional Solutions) Franchise — International operational growth YoY (%)(%) | -0.2% | 1.1% | 9.9% | 6.8% | 8.4% | 22.9% | 10.7% | 22.0% | 23.7% | 11.2% | 27.6% | 41.7% | |
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide reported growth YoY (%)(%) | 4.3% | 4.0% | 13.0% | 11.5% | 12.6% | 23.5% | 16.4% | 23.6% | 26.2% | 15.6% | 20.2% | 51.9% | |
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 4.1% | 3.1% | 10.5% | 10.1% | 11.6% | 22.3% | 17.7% | 24.2% | 26.5% | 18.0% | 22.5% | 52.3% | |
Cardiovascular (formerly Interventional Solutions) Franchise — Worldwide currency (FX) impact YoY (%)(%) | 0.2% | 0.9% | 2.5% | 1.4% | 1.0% | 1.2% | -1.3% | -0.6% | -0.3% | -2.4% | -2.3% | -0.4% | |
Electrophysiology sub-franchise — Worldwide sales ($M)($M)4 | 1,487 | 1,533 | 1,489 | 1,425 | 1,418 | 1,468 | 1,323 | 1,321 | 1,279 | 1,323 | 1,344 | 1,239 | |
Electrophysiology sub-franchise — U.S. sales ($M)($M)1 | 771 | 783 | 736 | 746 | 720 | 741 | 684 | 681 | 660 | 705 | 692 | 667 | |
Electrophysiology sub-franchise — U.S. operational growth YoY (%)(%) | 7.0% | 5.8% | 7.6% | 9.5% | 9.1% | 5.1% | -1.1% | 2.1% | 7.9% | 15.7% | 21.3% | 22.0% | |
Electrophysiology sub-franchise — International sales ($M)($M)1 | 717 | 749 | 753 | 679 | 698 | 728 | 638 | 640 | 619 | 618 | 652 | 572 | |
Electrophysiology sub-franchise — International operational growth YoY (%)(%) | 1.8% | 0.4% | 11.7% | 3.2% | 10.4% | 15.2% | 0.7% | 13.3% | 13.8% | 11.1% | 30.9% | 29.0% | |
Electrophysiology sub-franchise — Worldwide reported growth YoY (%)(%) | 4.9% | 4.4% | 12.6% | 7.9% | 10.8% | 11.0% | -1.6% | 6.6% | 10.2% | 10.6% | 23.0% | 24.7% | |
Electrophysiology sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 4.4% | 3.1% | 9.5% | 6.5% | 9.7% | 9.8% | -0.2% | 7.3% | 10.7% | 13.4% | 25.9% | 25.2% | |
Electrophysiology sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | 0.5% | 1.3% | 3.1% | 1.4% | 1.1% | 1.2% | -1.4% | -0.7% | -0.5% | -2.8% | -2.9% | -0.5% | |
Abiomed (Impella heart pumps) sub-franchise — Worldwide sales ($M)($M)4 | 412 | 440 | 488 | 460 | 423 | 448 | 420 | 384 | 362 | 379 | 371 | 340 | |
Abiomed (Impella heart pumps) sub-franchise — U.S. sales ($M)($M)1 | 335 | 342 | 389 | 358 | 336 | 360 | 339 | 308 | 293 | 309 | 303 | 276 | |
Abiomed (Impella heart pumps) sub-franchise — U.S. operational growth YoY (%)(%) | -0.3% | -4.8% | 14.5% | 16.5% | 14.5% | 16.6% | 11.9% | 11.3% | 15.4% | 13.2% | 15.0% | 8.8% | |
Abiomed (Impella heart pumps) sub-franchise — International sales ($M)($M)1 | 78 | 97 | 100 | 102 | 86 | 89 | 81 | 77 | 68 | 72 | 67 | 64 | |
Abiomed (Impella heart pumps) sub-franchise — International operational growth YoY (%)(%) | -6.5% | 9.2% | 13.9% | 25.4% | 20.2% | 18.4% | 23.6% | 21.1% | 20.1% | 25.3% | 14.7% | 27.1% | |
Abiomed (Impella heart pumps) sub-franchise — Worldwide reported growth YoY (%)(%) | -2.3% | -2.0% | 16.3% | 19.8% | 16.8% | 18.2% | 13.3% | 12.9% | 16.3% | 14.5% | 14.5% | 20.4% | |
Abiomed (Impella heart pumps) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -1.5% | -2.0% | 14.4% | 18.3% | 15.6% | 16.9% | 14.0% | 13.2% | 16.3% | 15.4% | 15.0% | 20.7% | |
Abiomed (Impella heart pumps) sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.8% | 0.0% | 1.9% | 1.5% | 1.2% | 1.3% | -0.7% | -0.3% | 0.0% | -0.9% | -0.5% | -0.3% | |
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide sales ($M)($M)4 | 325 | 335 | 305 | 318 | 278 | 292 | 258 | 258 | 229 | 77 | 0 | 0 | |
Shockwave (intravascular lithotripsy) sub-franchise — U.S. sales ($M)($M)1 | 261 | 268 | 242 | 238 | 220 | 233 | 206 | 202 | 163 | 77 | 0 | 0 | |
Shockwave (intravascular lithotripsy) sub-franchise — U.S. operational growth YoY (%)(%) | 18.8% | 14.6% | 17.8% | 18.0% | 34.4% | ||||||||
Shockwave (intravascular lithotripsy) sub-franchise — International sales ($M)($M)1 | 64 | 67 | 63 | 80 | 59 | 58 | 52 | 56 | 66 | 0 | 0 | 0 | |
Shockwave (intravascular lithotripsy) sub-franchise — International operational growth YoY (%)(%) | 11.2% | 15.4% | 19.3% | 40.7% | -12.4% | ||||||||
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide reported growth YoY (%)(%) | 16.8% | 14.6% | 18.5% | 23.3% | 21.2% | ||||||||
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 17.2% | 14.7% | 18.1% | 22.9% | 20.9% | ||||||||
Shockwave (intravascular lithotripsy) sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.4% | -0.1% | 0.4% | 0.4% | 0.3% | ||||||||
Other Cardiovascular sub-franchise — Worldwide sales ($M)($M)4 | 81 | 98 | 94 | 95 | 95 | 104 | 103 | 99 | 96 | 93 | 92 | 89 | |
Other Cardiovascular sub-franchise — U.S. sales ($M)($M)1 | 31 | 33 | 32 | 31 | 30 | 31 | 32 | 31 | 30 | 29 | 30 | 28 | |
Other Cardiovascular sub-franchise — U.S. operational growth YoY (%)(%) | 3.6% | 5.5% | 0.7% | -0.1% | 0.0% | 5.4% | 7.1% | 11.1% | 16.7% | 12.5% | 3.3% | ||
Other Cardiovascular sub-franchise — International sales ($M)($M)1 | 50 | 65 | 62 | 64 | 65 | 72 | 72 | 68 | 66 | 64 | 62 | 61 | |
Other Cardiovascular sub-franchise — International operational growth YoY (%)(%) | -23.1% | -13.2% | -17.5% | -8.8% | -2.5% | 11.6% | 17.4% | 12.3% | 7.5% | -1.0% | 11.5% | ||
Other Cardiovascular sub-franchise — Worldwide reported growth YoY (%)(%) | -13.9% | -5.7% | -9.1% | -4.6% | -0.7% | 10.8% | 12.5% | 11.8% | 10.4% | 0.3% | 5.7% | ||
Other Cardiovascular sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -14.7% | -7.5% | -11.9% | -6.1% | -1.7% | 9.7% | 14.1% | 12.0% | 10.2% | 2.8% | 8.8% | ||
Other Cardiovascular sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | 0.8% | 1.8% | 2.8% | 1.5% | 1.0% | 1.1% | -1.6% | -0.2% | 0.2% | -2.5% | -3.1% | ||
Surgery Franchise — Worldwide sales ($M)($M)6 | 2,528 | 2,653 | 2,511 | 2,644 | 2,542 | 2,555 | 2,396 | 2,507 | 2,434 | 2,488 | 2,416 | 2,530 | |
Surgery Franchise — U.S. sales ($M)($M)1 | 1,070 | 1,094 | 1,046 | 1,081 | 1,031 | 1,043 | 1,002 | 1,038 | 983 | 995 | 987 | 1,047 | |
Surgery Franchise — U.S. operational growth YoY (%)(%) | 3.7% | 5.0% | 4.4% | 4.2% | 4.9% | 4.8% | 1.5% | -0.9% | -1.1% | -2.0% | 1.2% | 4.6% | |
Surgery Franchise — International sales ($M)($M)1 | 1,459 | 1,559 | 1,465 | 1,563 | 1,511 | 1,512 | 1,394 | 1,469 | 1,451 | 1,493 | 1,429 | 1,484 | |
Surgery Franchise — International operational growth YoY (%)(%) | -4.2% | 0.5% | -1.1% | 3.4% | 2.2% | -0.2% | 0.8% | 1.4% | -0.3% | -0.7% | 2.3% | 7.8% | |
Surgery Franchise — Worldwide reported growth YoY (%)(%) | -0.6% | 3.9% | 4.8% | 5.5% | 4.4% | 2.7% | -0.8% | -0.9% | -1.8% | -4.1% | -0.7% | 6.1% | |
Surgery Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -1.0% | 2.3% | 1.2% | 3.7% | 3.3% | 1.8% | 1.1% | 0.4% | -0.7% | -1.2% | 1.9% | 6.4% | |
Surgery Franchise — Worldwide currency (FX) impact YoY (%)(%) | 0.4% | 1.6% | 3.6% | 1.8% | 1.1% | 0.9% | -1.9% | -1.3% | -1.1% | -2.9% | -2.6% | -0.3% | |
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide sales ($M)($M)4 | 1,155 | 1,189 | 1,123 | 1,175 | 1,165 | 1,164 | 1,073 | 1,151 | 1,109 | 1,141 | 1,087 | 1,167 | |
Advanced Surgery (endocutters, energy, biosurgicals) — U.S. sales ($M)($M)1 | 500 | 499 | 477 | 489 | 477 | 477 | 457 | 478 | 448 | 466 | 446 | 468 | |
Advanced Surgery (endocutters, energy, biosurgicals) — U.S. operational growth YoY (%)(%) | 5.1% | 4.7% | 4.2% | 2.5% | 6.2% | 2.2% | 2.7% | 2.0% | -1.4% | 0.1% | 0.2% | 2.5% | |
Advanced Surgery (endocutters, energy, biosurgicals) — International sales ($M)($M)1 | 654 | 691 | 646 | 687 | 688 | 687 | 616 | 673 | 661 | 675 | 641 | 698 | |
Advanced Surgery (endocutters, energy, biosurgicals) — International operational growth YoY (%)(%) | -5.7% | -1.9% | -1.0% | -0.8% | 2.1% | 0.2% | -1.0% | -1.6% | -5.1% | -6.4% | -0.7% | 7.2% | |
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide reported growth YoY (%)(%) | -0.9% | 2.2% | 4.6% | 2.2% | 5.0% | 2.0% | -1.2% | -1.4% | -4.7% | -6.7% | -2.8% | 5.1% | |
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -1.3% | 0.8% | 1.2% | 0.6% | 3.8% | 1.0% | 0.5% | -0.1% | -3.6% | -3.9% | -0.3% | 5.2% | |
Advanced Surgery (endocutters, energy, biosurgicals) — Worldwide currency (FX) impact YoY (%)(%) | 0.4% | 1.4% | 3.4% | 1.6% | 1.2% | 1.0% | -1.7% | -1.3% | -1.1% | -2.8% | -2.5% | -0.1% | |
General Surgery (wound closure / sutures) — Worldwide sales ($M)($M)4 | 1,373 | 1,464 | 1,388 | 1,468 | 1,378 | 1,391 | 1,323 | 1,357 | 1,325 | 1,346 | 1,330 | 1,364 | |
General Surgery (wound closure / sutures) — U.S. sales ($M)($M)1 | 568 | 596 | 569 | 592 | 555 | 567 | 544 | 560 | 535 | 528 | 542 | 579 | |
General Surgery (wound closure / sutures) — U.S. operational growth YoY (%)(%) | 2.4% | 5.2% | 4.5% | 5.6% | 3.8% | 7.2% | 0.5% | -3.1% | -0.9% | -3.7% | 2.1% | 6.4% | |
General Surgery (wound closure / sutures) — International sales ($M)($M)1 | 805 | 868 | 819 | 876 | 823 | 825 | 778 | 795 | 791 | 818 | 788 | 785 | |
General Surgery (wound closure / sutures) — International operational growth YoY (%)(%) | -3.0% | 2.5% | -1.3% | 6.9% | 2.2% | -0.6% | 2.3% | 4.0% | 4.0% | 4.5% | 4.8% | 8.3% | |
General Surgery (wound closure / sutures) — Worldwide reported growth YoY (%)(%) | -0.3% | 5.2% | 4.9% | 8.3% | 3.9% | 3.3% | -0.5% | -0.5% | 0.8% | -1.9% | 1.0% | 7.0% | |
General Surgery (wound closure / sutures) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | -0.8% | 3.6% | 1.1% | 6.3% | 2.9% | 2.5% | 1.6% | 1.0% | 2.0% | 1.2% | 3.7% | 7.5% | |
General Surgery (wound closure / sutures) — Worldwide currency (FX) impact YoY (%)(%) | 0.5% | 1.6% | 3.8% | 2.0% | 1.0% | 0.8% | -2.1% | -1.5% | -1.2% | -3.1% | -2.7% | -0.5% | |
Orthopaedics Franchise — Worldwide sales ($M)($M)8 | 2,345 | 2,418 | 2,383 | 2,438 | 2,274 | 2,305 | 2,241 | 2,315 | 2,191 | 2,312 | 2,340 | 2,268 | |
Orthopaedics Franchise — U.S. sales ($M)($M)1 | 1,448 | 1,470 | 1,435 | 1,520 | 1,396 | 1,420 | 1,384 | 1,460 | 1,359 | 1,422 | 1,448 | 1,425 | |
Orthopaedics Franchise — U.S. operational growth YoY (%)(%) | 3.8% | 3.5% | 3.7% | 4.2% | 2.7% | -0.2% | -4.4% | 2.4% | 0.7% | 2.5% | 6.2% | 2.9% | |
Orthopaedics Franchise — International sales ($M)($M)1 | 898 | 948 | 948 | 918 | 878 | 885 | 857 | 856 | 832 | 890 | 892 | 843 | |
Orthopaedics Franchise — International operational growth YoY (%)(%) | 2.9% | 5.3% | 2.4% | 2.3% | 1.9% | -4.0% | -0.9% | 2.5% | 2.2% | 4.5% | 2.7% | 8.8% | |
Orthopaedics Franchise — Worldwide reported growth YoY (%)(%) | 3.2% | 4.9% | 6.3% | 5.3% | 3.8% | -0.3% | -4.2% | 2.1% | 1.2% | 2.1% | 4.3% | 5.6% | |
Orthopaedics Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 3.4% | 4.2% | 3.2% | 3.5% | 2.4% | -1.6% | -3.1% | 2.5% | 1.3% | 3.3% | 4.8% | 5.0% | |
Orthopaedics Franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 0.7% | 3.1% | 1.8% | 1.4% | 1.3% | -1.1% | -0.4% | -0.1% | -1.2% | -0.5% | 0.6% | |
Hips reconstructive sub-franchise — Worldwide sales ($M)($M)4 | 419 | 441 | 436 | 439 | 405 | 421 | 409 | 418 | 381 | 417 | 422 | 398 | |
Hips reconstructive sub-franchise — U.S. sales ($M)($M)1 | 271 | 283 | 277 | 284 | 262 | 271 | 263 | 272 | 250 | 265 | 270 | 266 | |
Hips reconstructive sub-franchise — U.S. operational growth YoY (%)(%) | 3.5% | 4.6% | 5.2% | 4.3% | 4.7% | 2.1% | -2.5% | 2.5% | 4.8% | 5.8% | 12.1% | 6.3% | |
Hips reconstructive sub-franchise — International sales ($M)($M)1 | 148 | 158 | 159 | 154 | 144 | 150 | 146 | 146 | 131 | 152 | 152 | 132 | |
Hips reconstructive sub-franchise — International operational growth YoY (%)(%) | 3.0% | 3.0% | 0.3% | 0.4% | 5.9% | -4.3% | -0.8% | 11.7% | -3.2% | 6.8% | 3.3% | -3.9% | |
Hips reconstructive sub-franchise — Worldwide reported growth YoY (%)(%) | 3.1% | 4.9% | 6.5% | 4.7% | 6.4% | 1.0% | -3.1% | 5.2% | 1.7% | 4.9% | 8.1% | 3.4% | |
Hips reconstructive sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 3.3% | 4.0% | 3.5% | 2.9% | 5.1% | -0.2% | -1.9% | 5.6% | 1.9% | 6.2% | 8.7% | 2.7% | |
Hips reconstructive sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 0.9% | 3.0% | 1.8% | 1.3% | 1.2% | -1.2% | -0.4% | -0.2% | -1.3% | -0.6% | 0.7% | |
Knees reconstructive sub-franchise — Worldwide sales ($M)($M)4 | 386 | 410 | 420 | 432 | 377 | 389 | 389 | 398 | 352 | 394 | 401 | 387 | |
Knees reconstructive sub-franchise — U.S. sales ($M)($M)1 | 221 | 228 | 239 | 251 | 216 | 226 | 231 | 238 | 212 | 230 | 242 | 242 | |
Knees reconstructive sub-franchise — U.S. operational growth YoY (%)(%) | 2.1% | 1.1% | 3.3% | 5.1% | 2.1% | -1.9% | -4.3% | -1.5% | 2.2% | 4.2% | 6.9% | 4.5% | |
Knees reconstructive sub-franchise — International sales ($M)($M)1 | 165 | 182 | 181 | 181 | 160 | 164 | 158 | 160 | 140 | 163 | 160 | 144 | |
Knees reconstructive sub-franchise — International operational growth YoY (%)(%) | 4.4% | 10.3% | 6.5% | 9.2% | 10.9% | -2.9% | 2.1% | 11.3% | 7.0% | 17.7% | 13.1% | 15.6% | |
Knees reconstructive sub-franchise — Worldwide reported growth YoY (%)(%) | 2.5% | 5.5% | 7.9% | 8.6% | 7.0% | -1.1% | -3.0% | 3.1% | 4.0% | 8.4% | 9.0% | 9.2% | |
Knees reconstructive sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 3.1% | 5.0% | 4.6% | 6.8% | 5.6% | -2.3% | -1.7% | 3.3% | 4.1% | 9.5% | 9.3% | 8.4% | |
Knees reconstructive sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.6% | 0.5% | 3.3% | 1.8% | 1.4% | 1.2% | -1.3% | -0.2% | -0.1% | -1.1% | -0.3% | 0.8% | |
Trauma extremities sub-franchise — Worldwide sales ($M)($M)4 | 844 | 827 | 833 | 813 | 793 | 768 | 772 | 764 | 761 | 759 | 765 | 741 | |
Trauma extremities sub-franchise — U.S. sales ($M)($M)1 | 555 | 536 | 532 | 543 | 512 | 501 | 502 | 514 | 497 | 498 | 504 | 487 | |
Trauma extremities sub-franchise — U.S. operational growth YoY (%)(%) | 8.6% | 6.7% | 6.1% | 5.6% | 3.0% | 0.7% | -0.5% | 5.5% | 1.8% | 3.0% | 2.8% | 3.6% | |
Trauma extremities sub-franchise — International sales ($M)($M)1 | 288 | 291 | 301 | 270 | 281 | 267 | 270 | 250 | 265 | 260 | 261 | 255 | |
Trauma extremities sub-franchise — International operational growth YoY (%)(%) | 2.8% | 7.4% | 3.1% | 2.7% | 2.5% | -1.5% | 7.2% | -0.5% | 4.8% | 5.5% | -1.1% | 4.1% | |
Trauma extremities sub-franchise — Worldwide reported growth YoY (%)(%) | 6.4% | 7.6% | 8.0% | 6.4% | 4.2% | 1.2% | 0.9% | 3.0% | 2.6% | 2.8% | 1.0% | 4.4% | |
Trauma extremities sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 6.5% | 6.9% | 5.0% | 4.7% | 2.9% | -0.1% | 2.1% | 3.5% | 2.8% | 3.8% | 1.4% | 3.8% | |
Trauma extremities sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.1% | 0.7% | 3.0% | 1.7% | 1.3% | 1.3% | -1.2% | -0.5% | -0.2% | -1.0% | -0.4% | 0.6% | |
Spine, Sports & Other sub-franchise — Worldwide sales ($M)($M)4 | 697 | 740 | 694 | 756 | 698 | 727 | 671 | 735 | 696 | 743 | 752 | 742 | |
Spine, Sports & Other sub-franchise — U.S. sales ($M)($M)1 | 401 | 423 | 387 | 442 | 406 | 422 | 388 | 434 | 400 | 430 | 432 | 430 | |
Spine, Sports & Other sub-franchise — U.S. operational growth YoY (%)(%) | -1.2% | 0.2% | -0.1% | 1.9% | 1.3% | -1.7% | -10.2% | 1.1% | -3.6% | -0.8% | 6.5% | -0.7% | |
Spine, Sports & Other sub-franchise — International sales ($M)($M)1 | 296 | 317 | 307 | 312 | 293 | 305 | 283 | 300 | 296 | 314 | 320 | 311 | |
Spine, Sports & Other sub-franchise — International operational growth YoY (%)(%) | 2.0% | 1.9% | 0.7% | -0.7% | -4.8% | -6.4% | -8.9% | -2.9% | 0.4% | -2.9% | 0.9% | 16.5% | |
Spine, Sports & Other sub-franchise — Worldwide reported growth YoY (%)(%) | -0.1% | 1.8% | 3.5% | 2.8% | 0.3% | -2.1% | -10.8% | -0.9% | -1.9% | -3.1% | 3.2% | 6.2% | |
Spine, Sports & Other sub-franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 0.1% | 0.9% | 0.2% | 0.8% | -1.3% | -3.7% | -9.7% | -0.6% | -2.0% | -1.7% | 4.0% | 5.8% | |
Spine, Sports & Other sub-franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.2% | 0.9% | 3.3% | 2.0% | 1.6% | 1.6% | -1.1% | -0.3% | 0.1% | -1.4% | -0.8% | 0.4% | |
Vision Franchise — Worldwide sales ($M)($M)6 | 1,461 | 1,451 | 1,365 | 1,420 | 1,400 | 1,369 | 1,279 | 1,303 | 1,300 | 1,285 | 1,258 | 1,208 | |
Vision Franchise — U.S. sales ($M)($M)1 | 596 | 565 | 579 | 531 | 571 | 557 | 566 | 509 | 549 | 523 | 547 | 487 | |
Vision Franchise — U.S. operational growth YoY (%)(%) | 4.3% | 1.4% | 2.4% | 4.3% | 4.2% | 6.5% | 3.4% | 4.5% | 7.2% | -1.2% | -1.8% | 6.8% | |
Vision Franchise — International sales ($M)($M)1 | 865 | 887 | 785 | 889 | 828 | 813 | 713 | 794 | 751 | 763 | 710 | 721 | |
Vision Franchise — International operational growth YoY (%)(%) | 5.6% | 8.5% | 4.6% | 8.5% | 7.5% | 3.4% | 3.9% | 12.2% | 1.8% | 2.2% | -1.1% | 6.4% | |
Vision Franchise — Worldwide reported growth YoY (%)(%) | 4.4% | 6.0% | 6.7% | 8.9% | 7.7% | 6.5% | 1.7% | 7.9% | 3.5% | -1.7% | -3.3% | 5.5% | |
Vision Franchise — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 5.1% | 5.6% | 3.6% | 6.8% | 6.1% | 4.6% | 3.7% | 9.1% | 4.0% | 0.8% | -1.4% | 6.6% | |
Vision Franchise — Worldwide currency (FX) impact YoY (%)(%) | -0.7% | 0.4% | 3.1% | 2.1% | 1.6% | 1.9% | -2.0% | -1.2% | -0.5% | -2.5% | -1.9% | -1.1% | |
Contact Lenses / Other (ACUVUE) — Worldwide sales ($M)($M)4 | 1,053 | 1,025 | 969 | 1,008 | 1,018 | 965 | 919 | 937 | 968 | 918 | 910 | 882 | |
Contact Lenses / Other (ACUVUE) — U.S. sales ($M)($M)1 | 465 | 445 | 468 | 417 | 456 | 429 | 452 | 396 | 441 | 409 | 438 | 374 | |
Contact Lenses / Other (ACUVUE) — U.S. operational growth YoY (%)(%) | 1.9% | 3.6% | 3.7% | 5.3% | 3.5% | 4.8% | 3.1% | 6.0% | 10.2% | 0.2% | -1.4% | 8.9% | |
Contact Lenses / Other (ACUVUE) — International sales ($M)($M)1 | 588 | 580 | 501 | 592 | 562 | 536 | 467 | 541 | 527 | 509 | 472 | 508 | |
Contact Lenses / Other (ACUVUE) — International operational growth YoY (%)(%) | 6.2% | 7.9% | 1.7% | 5.3% | 3.4% | 1.4% | 2.4% | 8.5% | 0.6% | 1.2% | -3.1% | 7.2% | |
Contact Lenses / Other (ACUVUE) — Worldwide reported growth YoY (%)(%) | 3.5% | 6.1% | 5.5% | 7.6% | 5.2% | 5.1% | 1.0% | 6.3% | 4.2% | -2.2% | -4.6% | 6.1% | |
Contact Lenses / Other (ACUVUE) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 4.3% | 6.0% | 2.7% | 5.3% | 3.5% | 2.9% | 2.7% | 7.4% | 4.7% | 0.7% | -2.3% | 7.9% | |
Contact Lenses / Other (ACUVUE) — Worldwide currency (FX) impact YoY (%)(%) | -0.8% | 0.1% | 2.8% | 2.3% | 1.7% | 2.2% | -1.7% | -1.1% | -0.5% | -2.9% | -2.3% | -1.8% | |
Surgical Vision (intraocular lenses / cataract) — Worldwide sales ($M)($M)4 | 408 | 426 | 396 | 411 | 383 | 403 | 361 | 365 | 333 | 367 | 348 | 326 | |
Surgical Vision (intraocular lenses / cataract) — U.S. sales ($M)($M)1 | 132 | 120 | 111 | 113 | 116 | 128 | 114 | 113 | 108 | 113 | 110 | 114 | |
Surgical Vision (intraocular lenses / cataract) — U.S. operational growth YoY (%)(%) | 13.6% | -6.0% | -2.9% | 0.6% | 7.0% | 12.6% | 4.3% | -0.4% | -3.6% | -5.8% | -3.7% | 0.4% | |
Surgical Vision (intraocular lenses / cataract) — International sales ($M)($M)1 | 276 | 306 | 285 | 297 | 266 | 277 | 246 | 252 | 225 | 254 | 238 | 212 | |
Surgical Vision (intraocular lenses / cataract) — International operational growth YoY (%)(%) | 4.3% | 9.6% | 10.1% | 15.3% | 17.1% | 7.3% | 7.1% | 21.1% | 4.7% | 4.5% | 3.4% | 4.7% | |
Surgical Vision (intraocular lenses / cataract) — Worldwide reported growth YoY (%)(%) | 6.8% | 5.6% | 9.7% | 12.4% | 14.9% | 9.9% | 3.7% | 12.4% | 1.3% | -0.5% | 0.3% | 3.7% | |
Surgical Vision (intraocular lenses / cataract) — Worldwide operational (constant-currency) growth YoY (%)(%)1 | 7.1% | 4.7% | 6.0% | 10.8% | 13.8% | 8.9% | 6.2% | 13.6% | 1.9% | 1.2% | 1.1% | 3.1% | |
Surgical Vision (intraocular lenses / cataract) — Worldwide currency (FX) impact YoY (%)(%) | -0.3% | 0.9% | 3.7% | 1.6% | 1.1% | 1.0% | -2.5% | -1.2% | -0.6% | -1.7% | -0.8% | 0.6% | |
Total segment income before tax ($M)($M)3 | 5,842 | 7,426 | 6,556 | 5,259 | 7,733 | 6,756 | 6,631 | 4,081 | 5,541 | 6,548 | 6,489 | 4,642 | |
Innovative Medicine segment income before tax ($M)($M)4 | 5,066 | 6,249 | 5,317 | 5,058 | 6,446 | 5,552 | 5,210 | 4,009 | 4,482 | 5,459 | 4,969 | 4,238 | |
Innovative Medicine — Cost of products sold ($M)($M) | 4,486 | 4,296 | 4,390 | 3,976 | 3,672 | 3,978 | 4,020 | 3,514 | 3,549 | 3,603 | 3,370 | ||
Innovative Medicine — Selling, marketing and administrative expenses ($M)($M) | 3,035 | 3,130 | 2,918 | 3,456 | 2,869 | 2,789 | 2,261 | 3,312 | 2,491 | 2,665 | 2,438 | ||
Innovative Medicine — Research and development expense ($M)($M) | 3,888 | 2,875 | 2,813 | 3,466 | 2,944 | 2,869 | 2,548 | 3,698 | 4,213 | 2,722 | 2,896 | ||
Innovative Medicine — Other segment expense/(income), net ($M)($M) | 282 | -166 | -12 | -193 | -368 | 14 | -166 | -201 | -155 | 41 | -111 | ||
MedTech segment income before tax ($M)($M)4 | 776 | 1,177 | 1,239 | 201 | 1,287 | 1,204 | 1,421 | 72 | 1,059 | 1,089 | 1,520 | 404 | |
MedTech — Cost of products sold ($M)($M) | 3,597 | 3,737 | 3,701 | 3,973 | 3,612 | 3,638 | 3,326 | 3,596 | 3,381 | 3,248 | 3,120 | ||
MedTech — Selling, marketing and administrative expenses ($M)($M) | 3,014 | 3,069 | 2,906 | 3,035 | 2,801 | 2,862 | 2,656 | 2,836 | 2,723 | 2,671 | 2,582 | ||
MedTech — Research and development expense ($M)($M) | 764 | 778 | 714 | 786 | 728 | 647 | 677 | 1,600 | 739 | 718 | 646 | ||
MedTech — Other segment expense/(income), net ($M)($M) | 491 | 165 | 76 | 806 | 2 | 190 | -60 | 84 | -11 | 231 | -47 | ||
Consolidated earnings before provision for taxes on income ($M)($M) | 34 | 6,747 | 5,990 | 4,966 | 7,493 | 6,491 | 13,631 | 3,887 | 3,338 | 5,748 | 3,714 | 4,826 | |
Consolidated total assets ($M)($M)2 | 197,425 | 201,061 | 200,894 | 199,210 | 192,816 | 193,389 | 193,671 | 180,104 | 178,287 | 181,088 | 171,966 | 167,558 | |
Total segment identifiable assets ($M)($M) | 165,158 | 165,437 | 164,297 | 164,539 | 160,924 | 162,232 | 143,838 | 141,392 | 133,034 | ||||
General corporate / unallocated assets ($M)($M) | 32,267 | 35,624 | 36,597 | 34,671 | 31,892 | 31,157 | 49,833 | 38,712 | 34,524 | ||||
Additions to property, plant and equipment — Consolidated ($M)($M)4 | 1,362 | 1,321 | 1,049 | 1,837 | 1,157 | 1,043 | 795 | 1,612 | 1,029 | 976 | 807 | ||
Total segment additions to PP&E ($M)($M) | 1,303 | 1,246 | 1,017 | 1,737 | 1,082 | 1,002 | 756 | 1,553 | 973 | 902 | 725 | ||
Innovative Medicine additions to PP&E ($M)($M) | 704 | 653 | 508 | 910 | 479 | 411 | 276 | 739 | 418 | 321 | 232 | ||
MedTech additions to PP&E ($M)($M) | 599 | 593 | 509 | 827 | 603 | 591 | 480 | 814 | 555 | 581 | 493 | ||
General corporate additions to PP&E ($M)($M) | 59 | 75 | 32 | 100 | 75 | 41 | 39 | 59 | 56 | 74 | 82 | ||
Depreciation and amortization — Consolidated ($M)($M)4 | 2,117 | 1,959 | 2,004 | 2,011 | 1,777 | 1,943 | 1,772 | 1,896 | 1,846 | 1,782 | 1,815 | 1,843 | |
Total segment depreciation and amortization ($M)($M) | 2,053 | 1,904 | 1,939 | 1,941 | 1,718 | 1,883 | 1,720 | 1,834 | 1,750 | 1,656 | 1,757 | ||
Innovative Medicine depreciation and amortization ($M)($M) | 800 | 800 | 1,036 | 1,015 | 600 | 800 | 884 | 967 | 700 | 700 | 1,011 | 1,647 | |
MedTech depreciation and amortization ($M)($M) | 500 | 500 | 903 | 926 | 500 | 500 | 836 | 867 | 500 | 400 | 746 | 1,843 | |
General corporate depreciation and amortization ($M)($M) | 64 | 55 | 65 | 70 | 59 | 60 | 52 | 62 | 96 | 126 | 58 | ||
Goodwill — Consolidated carrying value ($M)($M)2 | 48,474 | 48,479 | 48,558 | 48,772 | 48,048 | 48,117 | 44,468 | 44,200 | 44,799 | 44,250 | 36,616 | 36,558 | |
Innovative Medicine goodwill ($M)($M) | 14,748 | 14,755 | 14,812 | 14,967 | 14,268 | 14,326 | 10,907 | 10,692 | 11,112 | 10,768 | 10,552 | 10,407 | |
MedTech goodwill ($M)($M) | 33,726 | 33,724 | 33,746 | 33,805 | 33,780 | 33,791 | 33,561 | 33,508 | 33,687 | 33,482 | 26,064 | 26,151 | |
Non-GAAP adjusted earnings before provision for taxes on income ($M)($M)2 | 7,672 | 8,660 | 7,821 | 7,046 | 8,436 | 8,188 | 8,011 | 5,421 | 7,277 | 8,404 | 7,877 | 6,237 | |
Non-GAAP adjusted pre-tax profit margin (% to sales)(%) | 30.2% | 34.2% | 32.5% | 28.7% | 35.2% | 34.5% | 36.6% | 24.1% | 32.4% | 37.4% | 36.8% | 29.2% | |
Non-GAAP adjusted pre-tax earnings growth YoY (%)(%) | -9.1% | 5.8% | -2.4% | 30.0% | 15.9% | -2.6% | 1.7% | -13.1% | -9.4% | 5.0% | 4.5% | -3.8% | |
Non-GAAP adjusted net earnings ($M)($M)5 | 6,339 | 7,081 | 6,614 | 6,009 | 6,801 | 6,699 | 6,706 | 4,946 | 5,876 | 6,840 | 6,580 | 5,562 | |
Non-GAAP adjusted net profit margin (% to sales)(%) | 25.0% | 28.0% | 27.5% | 24.5% | 28.3% | 28.2% | 30.6% | 22.0% | 26.1% | 30.5% | 30.8% | 26.0% | |
Non-GAAP adjusted net earnings growth YoY (%)(%) | -6.8% | 5.7% | -1.4% | 21.5% | 15.7% | -2.1% | 1.9% | -11.1% | -13.3% | 1.6% | 3.8% | 2.4% | |
Pre-tax Non-GAAP adjustment — Intangible asset amortization expense ($M)($M) | 1,240 | 1,245 | 1,247 | 1,186 | 1,048 | 1,267 | 1,120 | 1,171 | 1,171 | 1,106 | 1,078 | 1,148 | |
Pre-tax Non-GAAP adjustment — Litigation-related expense/(gain), net ($M)($M) | 5,519 | 267 | 330 | 854 | 15 | 57 | -6,966 | -16 | 2,388 | 352 | 2,726 | 166 | |
Pre-tax Non-GAAP adjustment — Restructuring-related expense ($M)($M) | 195 | 276 | 62 | 210 | 168 | 79 | 55 | 62 | 47 | -11 | 171 | 139 | |
Non-GAAP adjusted diluted net earnings per share ($)($)2 | 2.59 | 2.90 | 2.70 | 2.46 | 2.80 | 2.77 | 2.77 | 2.04 | 2.42 | 2.82 | 2.71 | 2.29 | |
Operational (constant-currency) adjusted diluted EPS ($)($) | 2.61 | 2.86 | 2.57 | 2.35 | 2.72 | 2.71 | 2.81 | 2.05 | 2.41 | 2.82 | 2.72 | 2.28 | |
Non-GAAP adjusted diluted EPS growth YoY (%)(%) | -7.5% | 4.7% | -2.5% | 20.6% | 15.7% | -1.8% | 2.2% | -10.9% | -9.0% | 10.2% | 12.4% | 11.7% | |
Non-GAAP adjusted effective tax rate (%)(%)1 | 17.4% | 18.2% | 15.4% | 14.7% | 19.4% | 18.2% | 16.3% | 8.8% | 19.3% | 18.6% | 16.5% | 10.8% | |
GAAP effective tax rate (%)(%) | -517.6% | 18.0% | 12.6% | -3.0% | 31.2% | 14.7% | 19.3% | 11.7% | 19.3% | 18.5% | 12.4% | 14.4% | |
GAAP gross profit ($M)($M)6 | 17,302 | 17,259 | 15,956 | 16,596 | 16,690 | 16,115 | 14,536 | 15,392 | 15,508 | 15,578 | 14,872 | 14,597 | |
GAAP gross profit margin (% to sales)(%) | 68.1% | 68.2% | 66.3% | 67.6% | 69.6% | 67.9% | 66.4% | 68.4% | 69.0% | 69.4% | 69.6% | 68.2% | |
Cost of products sold (% to sales)(%) | 31.9% | 31.8% | 33.7% | 32.4% | 30.4% | 32.1% | 33.6% | 31.6% | 31.0% | 30.6% | 30.4% | 31.8% | |
Selling, marketing and administrative expenses (% to sales)(%) | 24.7% | 25.4% | 25.1% | 27.5% | 24.7% | 24.8% | 23.3% | 28.6% | 24.3% | 25.3% | 24.6% | 27.1% | |
Research and development expense (% to sales)(%) | 18.3% | 14.4% | 14.7% | 17.3% | 15.3% | 14.8% | 14.7% | 23.5% | 22.0% | 15.3% | 16.6% | 20.9% | |
GAAP earnings before provision for taxes (% to sales)(%) | 0.1% | 26.7% | 24.9% | 20.2% | 31.2% | 27.3% | 62.3% | 17.3% | 14.9% | 25.6% | 17.4% | 22.6% | |
GAAP net earnings margin (% to sales)(%) | 0.8% | 21.9% | 21.8% | 20.8% | 21.5% | 23.3% | 50.2% | 15.2% | 12.0% | 20.9% | 15.2% | 19.3% | |
Full-Year Guidance — Estimated reported sales midpoint ($B)4 | 101.20 | 101.10 | 100.80 | 100.50 | 93.70 | 93.40 | 91.40 | 89.60 | 88.60 | 88.20 | 88.20 | 88.20 | |
Full-Year Guidance — Estimated reported sales growth midpoint (%)(%) | 7.4% | 7.3% | 7.0% | 6.7% | 5.7% | 5.4% | 3.1% | 1.0% | 5.4% | 5.0% | 5.0% | 5.0% | |
Full-Year Guidance — Operational sales midpoint ($B) | 100.70 | 100.60 | 100.20 | 100.00 | 93.20 | 92.90 | 92.00 | 91.30 | 89.60 | 89.40 | 88.00 | 88.60 | |
Full-Year Guidance — Operational sales growth midpoint (%)(%) | 6.9% | 6.8% | 6.4% | 6.2% | 5.1% | 4.8% | 3.8% | 3.0% | 6.6% | 6.4% | 5.8% | 5.5% | |
Full-Year Guidance — Adjusted operational sales growth ex-A&D midpoint (%)(%) | 6.6% | 6.5% | 6.1% | 5.9% | 3.8% | 3.5% | 2.5% | 2.5% | 6.0% | 5.8% | 5.8% | 5.5% | |
Full-Year Guidance — Adjusted diluted EPS midpoint ($)($)3 | 11.10 | 11.68 | 11.55 | 11.53 | 10.85 | 10.85 | 10.60 | 10.60 | 9.93 | 10.02 | 10.65 | 10.65 | |
Full-Year Guidance — Adjusted diluted EPS growth midpoint (%)(%) | 2.9% | 8.2% | 7.1% | 6.9% | 8.7% | 8.7% | 6.2% | 6.2% | 0.1% | 1.0% | 7.4% | 7.4% | |
Full-Year Guidance — Adjusted operational diluted EPS midpoint ($)($) | 11 | 11.58 | 11.40 | 11.38 | 10.68 | 10.68 | 10.60 | 10.85 | 9.91 | 10.05 | 10.68 | 10.65 | |
Full-Year Guidance — Adjusted operational diluted EPS growth midpoint (%)(%) | 2.0% | 7.3% | 5.7% | 5.5% | 7.0% | 7.0% | 6.2% | 8.7% | 0.1% | 1.3% | 7.7% | 7.4% | |
Accrued rebates, returns and promotions (GTN) liability on balance sheet ($M)($M) | 18,936 | 19,990 | 18,399 | 19,124 | 21,356 | 20,823 | 18,780 | 17,580 | 18,439 | 17,539 | 16,182 | 16,001 | |
Restructuring expense ($M)($M) | 181 | 34 | 32 | 84 | 63 | 64 | 17 | 42 | 41 | -13 | 164 | 56 | |
Total inventories, net ($M)($M)3 | 15,377 | 15,144 | 14,583 | 14,191 | 14,146 | 13,412 | 12,659 | 12,444 | 12,603 | 12,169 | 11,383 | 11,181 | |
Raw materials and supplies ($M)($M) | 2,483 | 2,515 | 2,612 | 2,530 | 2,552 | 2,389 | 2,371 | 2,337 | 2,545 | 2,407 | 2,331 | 2,355 | |
Goods in process ($M)($M) | 3,930 | 4,224 | 4,033 | 3,828 | 3,763 | 3,971 | 3,203 | 2,815 | 2,989 | 2,556 | 2,172 | 1,952 | |
Finished goods ($M)($M) | 8,964 | 8,405 | 7,938 | 7,833 | 7,831 | 7,052 | 7,085 | 7,292 | 7,069 | 7,206 | 6,880 | 6,874 | |
Property, plant and equipment, net ($M)($M)2 | 24,104 | 23,582 | 23,270 | 23,169 | 22,338 | 21,949 | 20,871 | 20,518 | 20,479 | 19,748 | 19,632 | 19,898 | |
Property, plant and equipment, gross ($M)($M) | 55,472 | 55,518 | 54,695 | 54,364 | 53,375 | 52,472 | 49,884 | 48,768 | 49,274 | 48,035 | 47,585 | 47,776 | |
Less: Accumulated depreciation ($M)($M) | 31,368 | 31,936 | 31,425 | 31,195 | 31,037 | 30,523 | 29,013 | 28,250 | 28,795 | 28,287 | 27,953 | 27,878 | |
Intangible assets, net (excluding goodwill) ($M)($M)3 | 46,652 | 48,229 | 49,061 | 50,403 | 48,737 | 49,835 | 36,755 | 37,618 | 39,490 | 39,725 | 34,286 | 34,175 | |
Finite-lived intangible assets, net ($M)2 | |||||||||||||
Patents and trademarks, net ($M)($M) | 25,899 | 24,815 | 25,576 | 26,649 | 22,687 | 22,516 | 17,843 | 18,571 | 18,227 | 18,603 | 14,372 | 15,609 | |
Other finite-lived intangibles, net ($M)($M) | 5,688 | 5,949 | 6,184 | 6,363 | 6,469 | 7,423 | 6,611 | 6,766 | 7,209 | 7,158 | 7,188 | 7,637 | |
Finite-lived intangible assets, gross ($M)2 | |||||||||||||
Patents and trademarks, gross ($M)($M) | 60,575 | 58,542 | 58,515 | 59,156 | 54,026 | 53,272 | 45,591 | 44,695 | 44,926 | 43,438 | 39,198 | 40,417 | |
Other finite-lived intangibles, gross ($M)($M) | 21,153 | 21,283 | 21,340 | 21,361 | 21,179 | 21,910 | 20,493 | 20,310 | 20,715 | 20,176 | 19,930 | 20,322 | |
Intangible asset amortization expense ($M)($M)4 | 1,200 | 1,200 | 1,200 | 1,200 | 1,000 | 1,300 | 1,100 | 1,100 | 1,200 | 1,100 | 1,100 | 1,100 | |
Estimated future intangible amortization — Year 1 ($M)($M) | 4,400 | 4,400 | 4,400 | 5,100 | 4,000 | 4,000 | 3,400 | 4,000 | 3,900 | 3,900 | 3,500 | 4,300 | |
Estimated future intangible amortization — Year 2 ($M)($M) | 3,700 | 3,700 | 3,700 | 4,400 | 3,300 | 3,400 | 2,800 | 3,400 | 3,300 | 3,300 | 2,900 | 3,500 | |
Estimated future intangible amortization — Year 3 ($M)($M) | 3,600 | 3,600 | 3,600 | 3,700 | 2,600 | 2,700 | 2,200 | 2,800 | 2,700 | 2,700 | 2,300 | 2,900 | |
Estimated future intangible amortization — Year 4 ($M)($M) | 3,500 | 3,500 | 3,500 | 3,600 | 2,500 | 2,600 | 2,200 | 2,200 | 2,000 | 2,000 | 1,600 | 2,300 | |
Total long-term debt (including current maturities) ($M)1 | |||||||||||||
Long-term debt, noncurrent ($M)($M) | 35,799 | 37,344 | 37,527 | 39,438 | 39,408 | 39,235 | 38,355 | 30,651 | 31,289 | 31,636 | 25,082 | 25,881 | |
Cash dividends paid to shareholders ($M)($M)4 | 3,227 | 3,227 | 3,131 | 3,131 | 3,132 | 3,129 | 2,989 | 2,984 | 2,985 | 2,985 | 2,869 | 2,865 | |
Cash dividends paid per share ($)($) | 1.34 | 1.34 | 1.30 | 1.30 | 1.30 | 1.24 | 1.24 | 1.24 | 1.19 | ||||
Common stock repurchases ($M)($M) | 1,712 | 219 | -4,034 | 1,922 | 1,904 | -2 | 2,129 | 257 | 539 | 136 | 1,475 | 216 | |
Treasury stock shares held (M shares) | 712.73 | 711.62 | 713.26 | 711.90 | 713.65 | 713.06 | 714.22 | 712.92 | 712.54 | 713.00 | 713.12 | 712.76 | |
Treasury stock carrying value ($M)($M) | 76,184 | 75,863 | 76,264 | 75,624 | 75,887 | 75,713 | 75,906 | 75,680 | 75,619 | 75,689 | 75,710 | 75,662 | |
Stock-based compensation expense ($M)($M) | 357 | 458 | 300 | 355 | 347 | 410 | 288 | 262 | 295 | 341 | 302 | 116 | |
U.S. Producer Price Index (PPI) — Pharmaceutical Preparation Manufacturing (PCU325412325412)2 | 929.06 | 926.72 | 925.44 | 919.12 | 917.42 | 915.09 | 915.34 | 918.11 | 917.27 | 914.37 | 907.84 | 896.32 | |
U.S. Consumer Price Index (CPI) — Medical Care Commodities (CUSR0000SAM1) | 404.94 | 410.39 | 416.81 | 417.00 | 416.48 | 415.97 | 412.57 | 415.90 | 414.52 | 408.35 | 410.06 | ||
U.S. Consumer Price Index (CPI) — Medical Care Services (CUUR0000SAM2) | 654.45 | 651.42 | 648.16 | 638.15 | 631.04 | 623.98 | 618.85 | 612.81 | 611.70 | 606.32 | 597.15 | ||
135 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar: Johnson & Johnson operates on a 52/53-week fiscal year ending on the Sunday nearest December 31 (FY2025 ended December 28, 2025; Q1 2026 ended March 29, 2026; Q2 2026 ended June 28, 2026; Q3 2026 ended September 27, 2026).
- Core operational & financial KPIs (Groups 1–6) cover: (1) Consolidated & Geographic Revenue Disaggregation ($25,399M in Q3 2026 / $94,193M in FY25 across U.S. $14,959M and International $10,440M [Europe $5,405M, Asia-Pacific/Africa $3,650M, Western Hemisphere ex-U.S. $1,385M]) and Reported (+5.9%), Operational Constant-Currency (+6.0%), Currency FX (-0.1%), and Adjusted Operational ex-A&D (+6.1%) growth drivers across all regions; (2–3) Innovative Medicine Segment ($16,757M in Q3 2026 / $60,401M in FY25, +7.9% operational in Q3 2026) across all 6 Therapeutic Areas — Oncology ($7,602M in Q3 2026, +16.7% operational: DARZALEX $4,239M, ERLEADA $1,023M, CARVYKTI $710M, IMBRUVICA $563M, RYBREVANT/LAZCLUZE $320M, TECVAYLI $312M, TALVEY $171M, legacy ZYTIGA & VELCADE), Immunology ($4,221M: TREMFYA $2,396M, STELARA $716M, SIMPONI/SIMPONI ARIA $568M, REMICADE $394M including U.S. Exports), Neuroscience ($2,375M: INVEGA SUSTENNA/TRINZA $998M, SPRAVATO $624M, CAPLYTA $398M, CONCERTA $143M, legacy RISPERDAL CONSTA), Pulmonary Hypertension ($897M: UPTRAVI $483M, OPSUMIT/OPSYNVI $372M, legacy TRACLEER), Infectious Diseases ($813M: EDURANT $386M, PREZISTA/SYMTUZA $381M, legacy COVID-19 Vaccine), and Cardiovascular/Metabolism ($849M: XARELTO $653M, legacy INVOKANA & PROCRIT/EPREX) — each disaggregated by Worldwide, U.S., and International ($M and operational YoY %); (4) MedTech Segment ($8,642M in Q3 2026 / $33,792M in FY25, +2.5% operational) across Cardiovascular ($2,307M: Electrophysiology $1,487M, Abiomed $412M, Shockwave $325M), Surgery ($2,528M: Advanced $1,155M, General $1,373M), Orthopaedics ($2,345M: Trauma $844M, Spine/Sports & Other $697M, Hips $419M, Knees $386M), and Vision ($1,461M: Contact Lenses $1,053M, Surgical $408M), plus legacy Consumer Health franchises prior to the FY23Q3 Kenvue separation; (5) Segment Pre-Tax Income, Significant Segment Expenses under ASU 2023-07 (COGS, SM&A, R&D, Other), Identifiable Assets, CapEx, D&A, and Goodwill; and (6) Non-GAAP Adjusted Pre-Tax Profit ($7,672M / 30.2% margin in Q3 2026), Adjusted Net Earnings ($6,339M / 25.0% margin), Adjusted Diluted EPS ($2.59 in Q3 2026; $10.79 in FY25), Operational Adjusted EPS ($2.61), Adjusted Effective Tax Rate (17.4%), GAAP % to Sales ratios, and Full-Year 2026 Management Guidance ($101.2B reported sales / $11.10 adjusted EPS midpoint).
- Groups 7–11 cover: (7) Balance Sheet Accrued Rebates, Returns & Promotions (GTN) Liability ($18,864M at Q3 2026), Major Wholesaler Revenue Concentration (Cencora 31.3%, McKesson 21.8%, Cardinal Health 12.6% in FY25), Advertising ($1,800M in FY25), Shipping & Handling (% of sales), and Restructuring; (8) Inventories by Stage ($13,517M net at Q3 2026: Raw Materials $1,943M, WIP $3,581M, Finished Goods $7,993M), PP&E by Category ($22,226M net at Q3 2026), Geographic PP&E across U.S., Europe, APAC/Africa & Western Hemisphere, Intangible Assets ($35,882M net at Q3 2026 with 5-year amortization schedule), and Operating Leases; (9) Debt & 5-Year Maturity Schedule ($39,719M total long-term debt at Q3 2026), Dividends ($3,275M / $1.35 per share in Q3 2026), Share Repurchases, Stock-Based Compensation, Deferred Tax Assets/Liabilities by Attribute, and Unrecognized Tax Benefits ($3,904M at FY25); (10) Global Workforce (140,800 employees / 138,200 FTEs in 10-K; 139,769 in HRIS across 4 regions), L&D Spend ($128M) & Training Hours (33.8 hrs/employee), CEO Pay Ratio (360:1 / $91,000 median employee in FY25), Form 11-K J&J Savings Plan ($26.89B net assets / $51.46B Master Trust in FY25), and Defined Benefit Pension ($29,572M PBO / $35,914M plan assets / +$6,342M funded status at FY25) & Postretirement Plans; and (11) Assured ESG & Sustainability Metrics from the 2025 Health for Humanity Report & Form SD (Community Giving $5,543M, 200M VERMOX doses, $16.2B Global Tax Contribution, 407 regulatory / 29 FDA inspections, 0.25 TRIR, Scope 1/2/3 GHG emissions, 100% renewable electricity, Water, Waste, 39,825 suppliers / $32.3B spend, and 218 in-scope 3TG suppliers / 340 verified SORs).
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Dữ liệu cập nhật 2026-10-25.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Consolidated Revenue, Geographic Disaggregation & Constant-Currency Growth Drivers
Innovative Medicine — Oncology & Immunology Therapeutic Areas & Key Drugs
Innovative Medicine — Neuroscience, Pulmonary Hypertension, Infectious Diseases & CVM
- Neuroscience Therapeutic Area Total — Worldwide sales ($M) ($M)40 kỳ
- Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M)39 kỳ
- Infectious Diseases (ID) Therapeutic Area Total — Worldwide sales ($M) ($M)40 kỳ
- Cardiovascular / Metabolism / Other (CVM) Therapeutic Area Total — Worldwide sales ($M) ($M)40 kỳ
MedTech Franchises & Sub-Franchises (Plus Legacy Consumer Health)
Segment Profitability, Significant Segment Expenses (ASU 2023-07), Assets, CapEx & D&A
Non-GAAP Adjusted Earnings, Statement of Earnings Ratios (% to Sales) & Full-Year Guidance
- Non-GAAP adjusted earnings before provision for taxes on income ($M) ($M)40 kỳ
- Non-GAAP adjusted net earnings ($M) ($M)40 kỳ
- Non-GAAP adjusted diluted net earnings per share ($) ($)40 kỳ
- Non-GAAP adjusted effective tax rate (%) (%)40 kỳ
- GAAP gross profit ($M) ($M)38 kỳ
- Full-Year Guidance — Estimated reported sales midpoint ($B)17 kỳ
- Full-Year Guidance — Adjusted diluted EPS midpoint ($) ($)17 kỳ
Gross-to-Net (GTN) Rebates Liability, Wholesaler Concentration, Advertising & Restructuring
Manufacturing, Inventories, PP&E, Geographic Long-Lived Assets, Intangibles & Leases
Debt, Maturities, Capital Allocation, Share Repurchases & Income Taxes
Workforce, Executive Compensation, Form 11-K Savings Plan & Defined Benefit Pensions
- Global employees — Total headcount (Form 10-K)13 kỳ
- Employee learning & development (L&D) total spend ($M) ($M)3 kỳ
- CEO to median-paid employee pay ratio (X:1)7 kỳ
- J&J Savings Plan (Form 11-K) — Net assets available for benefits ($) ($)8 kỳ
- Defined benefit retirement (pension) plans — Projected benefit obligation (PBO) ($M) ($M)11 kỳ
- Other postretirement benefit plans — Benefit obligation (APBO) ($M) ($M)11 kỳ
ESG, Global Health Access, Environmental Stewardship, Quality/FDA & Supply Chain
- Community giving — Total product donations and cash contributions ($M) ($M)3 kỳ
- Total global tax contribution ($B)3 kỳ
- Regulatory inspections of J&J sites by worldwide health authorities3 kỳ
- Employee & contingent worker safety — Total recordable injury rate (TRIR)3 kỳ
- Scope 1 + Scope 2 (market-based) GHG emissions (MT CO2e)3 kỳ
- Total enterprise energy consumption (MWh)3 kỳ
- Total water withdrawn (million cubic meters)3 kỳ
- Total operational waste generated (metric tons)3 kỳ
- Global supply base — Total number of J&J suppliers3 kỳ
Industry & Macro Healthcare Benchmarks (FRED) & Core Financial Statements
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Johnson & Johnson
- Form 10-Q (filed 2026-10-21) ↗
- Form 10-K (filed 2026-02-11) ↗
- J&J 2025 Health for Humanity Report ↗
- Form 8-K (a2026q3exhibit991.htm, filed 2026-10-13) ↗
- Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
- FRED (PCU325412325412) ↗
- Form 10-Q (filed 2023-07-31) ↗
- Form 10-K (filed 2023-02-16) ↗
- Form 10-K (jnj-20251228.htm, filed 2026-02-11) ↗
- Proxy Statement (DEF 14A) (jnj-20260309.htm, filed 2026-03-11) ↗
- Form 11-K (Savings Plan) (jnj-20260624.htm, filed 2026-06-25) ↗
See a number that looks wrong?